Methods of nucleic acid sample preparation

ABSTRACT

Aspects of the technology disclosed herein relate to methods of preparing and analyzing nucleic acids. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.

RELATED APPLICATIONS

This application is a continuation application of U.S. Ser. No.15/706,642, filed Sep. 15, 2017, now U.S. Pat. No. 10,704,082, whichclaims priority under 35 U.S.C. § 119(e) to U.S. Provisional PatentApplication No. 62/395,339, filed Sep. 15, 2016, each of which is herebyincorporated by reference in its entirety.

TECHNICAL FIELD

The technology described herein relates to methods and compositionsuseful in the preparation of nucleic acid molecules for analysis.

REFERENCE TO SEQUENCE LISTING SUBMITTED AS A TEXT FILE VIA EFS-WEB

The instant application contains a sequence listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Jul. 2, 2020, isnamed A110070013US03-SEQ-JIB.txt and is 2,221 bytes in size.

BACKGROUND

Target enrichment prior to next-generation sequencing is morecost-effective than whole genome, whole exome, and whole transcriptomesequencing and therefore more practical for broad implementation; bothfor research discovery and clinical applications. For example, highcoverage depth afforded by target enrichment approaches enables a widerdynamic range for allele counting (in gene expression and copy numberassessment) and detection of low frequency mutations, which isadvantageous for evaluating somatic mutations in cancer. Examples ofcurrent enrichment protocols for next generation sequencing includehybridization-based capture assays (TruSeq Capture, Illumina; SureSelectHybrid Capture, Agilent) and polymerase chain reaction (PCR)-basedassays (HaloPlex, Agilent; AmpliSeq, Ion Torrent; TruSeq Amplicon,Illumina; emulsion/digital PCR, Raindance). Hybridization-basedapproaches capture not only the targeted sequences covered by thecapture probes but also near off-target bases that consume sequencingcapacity. In addition, these methods are relatively time-consuming,labor-intensive, and suffer from a relatively low level of specificity.

SUMMARY

Aspects of the technology disclosed herein relate to methods ofpreparing and analyzing nucleic acids. In some embodiments, methods andcompositions useful in the preparation of nucleic acid samples forsequence analysis (e.g., using next-generating sequencing) are providedherein. In some embodiments, techniques described herein are related tomethods of determining a nucleic acid sequence. In some embodiments,methods and compositions described herein relate to the enrichment ofnucleic acids comprising one or more target nucleotide sequences priorto sequencing. In some aspects, the disclosure provides methods ofpreparing nucleic acids (e.g., for use in a sequencing analysis) thatinvolve adding one or more capture moiety modified nucleotides to anucleic acid. In some embodiments, the methods further involve ligatingan adapter nucleic acid to the nucleic acid to which the capture moietymodified nucleotide has been added to produce a ligation product. Insome embodiments, the methods further involve capturing the ligationproduct by contacting the ligation product with a binding partner of acapture moiety of the capture moiety modified nucleotide. In someembodiments, the methods further involve amplifying the ligationproduct, e.g., by polymerase chain reaction or another suitableamplification approach. In some embodiments, methods are provided forpreparing nucleic acids that involve adding one or more nucleotides to a3′ end of a nucleic acid (e.g., a double-stranded nucleic acid)comprising a target nucleotide sequence, in which at least one of theone or more nucleotides is a capture moiety modified nucleotide. In someembodiments, presence of the capture moiety modified nucleotide at the3′-end of the nucleic acid facilitates isolation, purification and/orwashing of the nucleic acid while avoiding incorporation of modifiednucleotides (e.g., randomly) throughout the nucleic acid. In someembodiments, methods are provided for preparing nucleic acids thatinvolve incorporating one or more nucleotides into a nucleic acid (e.g.,a double-stranded nucleic acid) comprising a target nucleotide sequence,in which at least one of the one or more nucleotides is a capture moietymodified nucleotide. In some embodiments, the one or more nucleotidesare incorporated using a primer (e.g., a reverse transcription primer).In some embodiments, the one or more nucleotides are incorporated duringan earlier step of preparing the nucleic acids. For example, in someembodiments, the one or more nucleotides are incorporated duringfragmentation, random priming, first strand synthesis, second strandsynthesis, and/or end repair.

In some aspects, the disclosure provides methods of preparing nucleicacids for analysis, in which the methods involve: (a) adding one or morenucleotides to a 3′ end of a double-stranded nucleic acid comprising atarget nucleotide sequence, wherein at least one of the one or morenucleotides is a capture moiety modified nucleotide; (b) ligating anadapter nucleic acid to the double-stranded nucleic acid to which thecapture moiety modified nucleotide has been added to produce a ligationproduct, wherein a sequence of one or more nucleotides at a 3′ end ofthe adapter nucleic acid is complementary with the one or morenucleotides added to the 3′ end of the double-stranded nucleic acid instep (a); (c) capturing the ligation product by contacting the ligationproduct with a binding partner of a capture moiety of the capture moietymodified nucleotide; and (d) amplifying the ligation product bypolymerase chain reaction using a first target-specific primer thatspecifically anneals to the target nucleotide sequence and a firstadapter primer that specifically anneals to a complementary sequence ofthe adapter nucleic acid.

In some embodiments, step (b) comprises combining the adapter nucleicacid, the double-stranded nucleic acid, and a ligase under conditions inwhich the ligase ligates the adapter nucleic acid to the double-strandednucleic acid. In some embodiments, the adapter nucleic acid that iscombined with the double-stranded nucleic acid comprises a duplexportion and an overhang sequence. In some embodiments, the overhangsequence comprises the sequence of one or more nucleotides at the 3′ endof the adapter nucleic acid that is complementary with the one or morenucleotides added to the 3′ end of the double stranded nucleic acid instep (a).

In some embodiments, step (b) comprises combining the adapter nucleicacid, the double-stranded nucleic acid, and a ligase under conditions inwhich the ligase ligates the adapter nucleic acid to the double-strandednucleic acid, wherein the adapter nucleic acid that is combined with thedouble-stranded nucleic acid is single-stranded.

In some embodiments, methods provided herein further comprise: (e)amplifying an amplification product of step (d) by polymerase chainreaction using a second adapter primer and a second target-specificprimer. In some embodiments, the second target-specific primer is nestedrelative to the first target-specific primer. In some embodiments, thesecond target-specific primer comprises a 5′ tail that does not annealto the target nucleotide sequence. In some embodiments, the methodfurther comprises adding an additional primer comprising a 3′ portionthat is identical to the 5′ tail of the second target-specific primer.

In some embodiments, the capture moiety is a biotin moiety. In someembodiments, the biotin moiety comprises biotin-triethylene glycol,bis-biotin, photocleavable biotin, desthiobiotin,desthiobiotin-triethylene glycol, or biotin azide.

In some embodiments, the capture moiety modified nucleotide comprises anucleobase selected from the group consisting of adenine, guanine,thymine, uracil, and cytosine, or a derivative thereof. In someembodiments, the capture moiety modified nucleotide comprises an adeninenucleobase or derivative thereof. In some embodiments, the capturemoiety is covalently linked to the adenine nucleobase or derivativethereof at position 5, 6, 7 or 8. In some embodiments, the capturemoiety is covalently linked to the adenine nucleobase at position 7. Insome embodiments, position 7 of the adenine nucleobase is a carbon atom.

In some embodiments, the biotin moiety is covalently linked to thenucleobase via a linker of any appropriate length. In some embodiments,the biotin moiety is covalently linked to the nucleobase, e.g., via alinker of 5 to 20 atoms in length (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20 atoms in length). In some embodiments, thecapture moiety modified nucleotide is biotin-n-dNTP, wherein n is aninteger from 5 to 20 representing the number of linker atoms between acarbonyl-group of the biotin moiety and the position of attachment on anucleobase of the NTP.

In some embodiments, the binding partner is streptavidin. In someembodiments, the streptavidin is attached to a paramagnetic bead.

In some embodiments, in step (a), one nucleotide is added to the 3′ endof the double-stranded nucleic acid comprising the target nucleotidesequence.

In some embodiments, methods further comprise a purification ofnon-specific nucleic acids. In some embodiments, methods provided hereinfurther comprise a reaction cleanup or a washing step after step (b) andbefore step (c). In some embodiments, the method further comprises,after step (c) and prior to step (d): i) immobilizing thedouble-stranded nucleic acid, which comprises the capture moietymodified nucleotide, on a paramagnetic substrate or surface (e.g., apolystyrene paramagnetic bead); and ii) washing the immobilizeddouble-stranded nucleic acid. In some embodiments, the method furthercomprises, after step (ii): iii) releasing the washed immobilizeddouble-stranded nucleic acid from the paramagnetic substrate or surface.In some embodiments, the washed immobilized double-stranded nucleic acidis released from the paramagnetic substrate or surface by contactingwith a chemical reagent and/or applying heat. In some embodiments, thechemical reagent is a base or basic solution. In some embodiments, thechemical reagent comprises sodium hydroxide (NaOH). It should beappreciated that, in some embodiments, contacting can involve mixing twosolutions (e.g., a solution comprising a base and a solution comprisinga washed immobilized nucleic acid), adding a solid to a solution, oradding a solution to a solid. In some embodiments, the washedimmobilized double-stranded nucleic acid is released from theparamagnetic substrate or surface by contacting with NaOH and heating(e.g., heating to above room temperature, such as a temperature in arange of 25 to 90° C., 25 to 70° C., 25 to 50° C., 35 to 65° C., 35 to45° C., 30 to 40° C., 40 to 50° C.). In some embodiments, the washedimmobilized double-stranded nucleic acid remains on the paramagneticsubstrate or surface, e.g., for further preparation for analysis. Insome embodiments, the washed immobilized double-stranded nucleic acid isreleased from the paramagnetic substrate or surface prior to furtherpreparation for analysis.

In some embodiments, methods provided herein further comprise, prior tostep (a), 5′ phosphorylating the double-stranded nucleic acid.

In some embodiments, method provided herein further comprise, prior tostep (a): i) preparing cDNA by conducting a randomly-primed first strandsynthesis reaction using an RNA preparation as a template and a secondstrand synthesis reaction using a product of the randomly-primed firststrand synthesis reaction as a template; and ii) end repairing the cDNAto produce a blunt-ended, double-stranded nucleic acid. In someembodiments, the method further comprises, after step ii): iii)immobilizing the double-stranded nucleic acid, which comprises thecapture moiety modified nucleotide, on a paramagnetic substrate orsurface; iv) washing the immobilized double-stranded nucleic acid; andv) releasing the washed immobilized double-stranded nucleic acid fromthe paramagnetic substrate or surface. In some embodiments, theparamagnetic substrate or surface comprises a coating (e.g., apolystyrene coating). In some embodiments, cDNA is prepared for analysisby conducting gene specifically-primed first strand synthesis. In someembodiments, end repairing involves blunting and/or phosphorylating DNAends.

In some embodiments, methods further comprise, after step (e), (f)immobilizing the amplification product of step (e) on a paramagneticsubstrate or surface; (g) washing the immobilized amplification product;and (h) releasing the washed immobilized amplification product from theparamagnetic substrate or surface. In some embodiments, the methodfurther comprises one or more intervening washing steps (e.g., washingof amplification products between any step of the methods describedherein). For example, in some embodiments, the method further comprisesa washing step after step (e) and before step (f).

In some embodiments, in step (b), the double-stranded nucleic acid isligated to the adapter nucleic acid in the presence of a crowding agent.In some embodiments, the crowding agent is polyethylene glycol in anamount representing 5% to 50% of a ligation mixture. In someembodiments, the double-stranded nucleic acid is blunt-ended. In someembodiments, the double-stranded nucleic acid comprises overhangs.

In some aspects, the disclosure provides methods of preparing nucleicacids for analysis, in which the methods involve: (a) preparing a cDNAby conducting a randomly-primed first strand synthesis reaction using anRNA preparation as a template and a second strand synthesis reactionusing a product of the randomly-primed first strand synthesis reactionas a template, wherein the RNA preparation comprises a target nucleotidesequence; (b) end repairing the cDNA to produce a blunt-ended,double-stranded nucleic acid comprising the target nucleotide sequence;(c) immobilizing the blunt-ended, double-stranded nucleic acid on aparamagnetic substrate or surface; (d) washing the immobilizedblunt-ended, double-stranded nucleic acid; (e) releasing the washedimmobilized blunt-ended, double-stranded nucleic acid from theparamagnetic substrate or surface; (f) adding one or more nucleotides tothe 3′ end of the released blunt-ended, double-stranded nucleic acid;(g) ligating an adapter that comprises a ligatable duplex portion and anoverhang sequence to the nucleic acid produced in step (f) to produce aligation product, wherein the overhang sequence is complementary withthe one or more nucleotides; (h) amplifying the ligation product bypolymerase chain reaction using a first target-specific primer thatspecifically anneals to the target nucleotide sequence and a firstadapter primer that specifically anneals to a complementary sequence ofthe adapter nucleic acid; (i) amplifying an amplification product ofstep (h) by polymerase chain reaction using a second adapter primer anda second target-specific primer, wherein the second target-specificprimer is nested relative to the first target-specific primer; (j)immobilizing the amplification product of step (i) to a paramagneticsubstrate or surface; (k) washing the immobilized amplification product;and (1) releasing the washed immobilized amplification product from theparamagnetic substrate or surface. In some embodiments, step (h) isperformed without washing the ligation product.

In some aspects, the disclosure provides methods of preparing nucleicacids for analysis, in which the methods involve: (a) preparing a cDNAby conducting a randomly-primed first strand synthesis reaction using anucleic acid preparation as a template and a second strand synthesisreaction using a product of the randomly-primed first strand synthesisreaction as a template, wherein the nucleic acid preparation comprises atarget nucleotide sequence; (b) end repairing the cDNA to produce ablunt-ended, double-stranded nucleic acid comprising the targetnucleotide sequence; (c) washing the blunt-ended, double-strandednucleic acid; (d) adding one or more nucleotides to the 3′ end of thenucleic acid washed in step (c), optionally wherein at least one of theone or more nucleotides is a capture moiety modified nucleotide; (e)washing the nucleic acid produced in step (d); (f) ligating an adapternucleic acid that comprises a ligatable duplex portion and an overhangsequence to the nucleic acid washed in step (e) to produce a ligationproduct, wherein the overhang sequence is complementary with the one ormore nucleotides; (g) amplifying the ligation product by polymerasechain reaction using a first target-specific primer that specificallyanneals to the target nucleotide sequence and a first adapter primerthat specifically anneals to a complementary sequence of the adapternucleic acid; (h) amplifying an amplification product of step (g) bypolymerase chain reaction using a second adapter primer and a secondtarget-specific primer, wherein the second target-specific primer isnested relative to the first target-specific primer; and (j) washing theamplification product of step (h).

In some embodiments, the washing steps are performed using a solid-phasereversible immobilization technique.

In some embodiments, at least one of the one or more nucleotides is acapture moiety modified nucleotide, and the method further comprises,following step (f) and before step (g), capturing the ligation productusing an immobilized binding partner of the capture moiety of thecapture moiety modified nucleotide; and cleaning the captured ligationproduct. In some embodiments, the capture moiety comprises a biotinmoiety and the binding partner comprises streptavidin.

In some embodiments, the second adapter primer is nested relative to thefirst adapter primer. In some embodiments, the second adapter primerspecifically anneals to a complementary sequence of the adapter nucleicacid.

Other advantages and novel features of the present disclosure willbecome apparent from the following detailed description of variousnon-limiting embodiments of the invention when considered in conjunctionwith the accompanying figures. In cases where the present specificationand a document incorporated by reference include conflicting and/orinconsistent disclosure, the present specification shall control.

BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting embodiments of the present invention will be described byway of example with reference to the accompanying figures, which areschematic and are not intended to be drawn to scale. In the figures,each identical or nearly identical component illustrated is typicallyrepresented by a single numeral. For purposes of clarity, not everycomponent is labeled in every figure, nor is every component of eachembodiment of the invention shown where illustration is not necessary toallow those of ordinary skill in the art to understand the invention. Inthe figures:

FIG. 1 is an illustration of a process that allows for the capture of anadapter-ligated nucleic acid library.

FIG. 2 is an illustration of a method of preparing a high-fidelitynucleic acid sample for analysis.

FIG. 3 depicts a process of generating a double-stranded cDNA sampleusing a template RNA strand.

FIG. 4 depicts a process of generating a double-stranded cDNA sampleusing a template RNA strand, where captured ligation product is elutedfrom magnetic beads prior to amplification.

FIG. 5 is a depiction of a workflow for a method of preparing ahigh-fidelity nucleic acid sample for analysis.

FIG. 6 is an image representation of a gel that depicts a library samplethat has been end repaired without polymerase inactivation and a librarysample that has been end repaired following heat inactivation ofpolymerase.

FIG. 7 is an image representation of a gel that depicts adapter ligationefficiencies of samples ligated in the absence or presence of a crowdingagent.

FIG. 8A is a diagram illustrating the components that may comprise anadapter nucleic acid.

FIG. 8B is a diagram illustrating the components that may comprise asecond target-specific primer.

DETAILED DESCRIPTION

Among other aspects, the present disclosure provides improved techniquesrelated to the preparation of nucleic acid sample libraries foranalysis. As described herein, an adapter nucleic acid may be ligated toa nucleic acid comprising a target nucleotide sequence. The use ofadapter nucleic acids can be useful during library preparation andsequencing analysis, for example, by providing primer binding sites andmolecular barcode or index sequences. In some aspects, the presentdisclosure relates to improvements in processes related to adapterligation and adapter-ligated sample isolation that substantiallyimproves molecular barcode fidelity.

In some aspects, the disclosure relates to the recognition that,following adapter ligation, carryover of unligated adapter intosubsequent PCR reactions could result in an overabundance of molecularbarcodes. This overabundance, or inflation, of molecular barcodes canresult in false positives, as one molecule should only contain onebarcode. It is appreciated that, in some embodiments, unligated adaptercan, in some instances, prime off of a common region in existingfragments during PCR. Over multiple reaction cycles, additional copiesof a barcode or other artificial sequence can be integrated into asingle molecule. Accordingly, the inventors have recognized andappreciated the need for improved processes relating to the ligation ofadapters and the isolation of adapter-ligated library fragments.

In some aspects, the disclosure provides a method of preparing nucleicacids for analysis, comprising (a) adding a capture moiety modifiednucleotide to a 3′ end of a double-stranded nucleic acid (e.g., cDNA,gDNA), ligating an adapter nucleic acid to the double-stranded nucleicacid having the capture moiety modified nucleotide, and capturing theadapter-ligated nucleic acid with a binding partner of the capturemoiety modified nucleotide.

In some embodiments, the capture moiety modified nucleotide is a biotinmoiety modified nucleotide. A general depiction of this method is shownin FIG. 1 , which provides a non-limiting example of a method involvinga biotin moiety modified nucleotide. In this embodiment, a library ofblunt-ended, 5′ phosphorylated double-stranded nucleic acids 102 isprovided. Biotin-labeled ATP 104 is added to the 3′ ends of thedouble-stranded nucleic acids to produce a library 106 comprisingcapture moiety modified nucleotides at the 3′ ends of the fragments. Thelibrary fragments are ligated with an adapter 108 to produce a sample110 having unligated adapter along with adapter-ligated libraryfragments. Ligated library fragments are captured, or isolated, fromunligated adapter using a streptavidin coated surface to generate alibrary 112 that minimizes or eliminates the occurrence of unligatedadapter carryover. Although this example utilizes a biotin capturemoiety, any moiety that is capable of being specifically targeted forisolation (e.g., via an interaction with a binding partner) may besuitable in the techniques described herein.

Capture Moiety

Aspects of the techniques described herein relate to the use of acapture moiety to isolate a molecule of interest (e.g., a nucleic acid,a ligation product, etc.). As used herein, a “capture moiety” refers toa moiety that is configured to selectively interact with a bindingpartner for the purpose of capturing (e.g., isolating/purifying) themolecule of interest.

A capture moiety and a binding partner of the capture moiety maycomprise any suitable binding pair. In some embodiments, a binding paircan selectively interact through covalent or non-covalent binding. Insome embodiments, a binding pair can selectively interact byhybridization, ionic bonding, hydrogen bonding, van der Waalsinteractions, or any combination of these forces. In some embodiments, acapture moiety and/or binding partner can comprise, for example, biotin,avidin, streptavidin, digoxigenin, inosine, avidin, GST sequences,modified GST sequences, biotin ligase recognition (BiTag) sequences, Stags, SNAP-tags, enterokinase sites, thrombin sites, antibodies orantibody domains, antibody fragments, antigens, receptors, receptordomains, receptor fragments, or combinations thereof.

In some embodiments, a capture moiety comprises a biotin moiety. In someembodiments, techniques described herein are useful in preparing nucleicacid samples for analysis. Accordingly, in some embodiments, a nucleicacid molecule comprises a biotinylated capture moiety. In someembodiments, the nucleic acid molecule comprises at least one capturemoiety modified nucleotide comprising a biotin moiety. In someembodiments, the capture moiety modified nucleotide comprises thegeneral structure of formula (I):

As shown in formula (I), a capture moiety modified nucleotide maycomprise a biotin moiety attached to a nucleobase of a nucleotide. Forexample, in some embodiments, the biotin moiety comprisesbiotin-triethylene glycol, bis-biotin, photocleavable biotin,desthiobiotin, desthiobiotin-triethylene glycol, or biotin azide.Non-limiting examples of capture moiety modified nucleotides are shownin Table 1.

TABLE 1 Example structures of capture moiety modified nucleotides

In some embodiments, a capture moiety modified nucleotide comprises alinker between the capture moiety and a nucleobase of the nucleotide. Insome embodiments, the capture moiety is covalently linked to thenucleobase via a linker of any suitable length. In some embodiments, thecapture moiety is covalently linked to the nucleobase via a linker of 5to 20 atoms in length. In some embodiments, the linker comprises analiphatic chain. In some embodiments a linker comprises —(CH₂)n-,wherein n is an integer from 1 to 20, inclusive. In some embodiments, nis an integer from 1 to 10, inclusive. In certain embodiments, a linkercomprises a heteroaliphatic chain. In some embodiments, a linkercomprises a polyethylene glycol moiety. In some embodiments, a linkercomprises a polypropylene glycol moiety. In some embodiments, a linkercomprises —(CH₂CH₂O)n-, wherein n is an integer from 1 to 20, inclusive.In some embodiments, a linker comprises —(CH₂CH₂O)n-, wherein n is aninteger from 1 to 10, inclusive. In certain embodiments, a linkercomprises one or more arylenes. In some embodiments, a linker comprisesone or more phenylenes (e.g., para-substituted phenylene). In certainembodiments, a linker comprises a chiral center. In certain embodiments,a linker comprises one or more phosphates, an aliphatic chain, aheteroaliphatic chain, and one or more amides (e.g., —C(═O)NH—).

In some embodiments, a capture moiety modified nucleotide isbiotin-n-dNTP, wherein n is an integer from 5 to 20 representing thenumber of linker atoms between a carbonyl-group of the biotin moiety andthe position of attachment on a nucleobase of the NTP.

In some embodiments, a binding partner is attached to an insolublesupport. Thus, in some embodiments, the molecule of interest may beimmobilized on an insoluble support through a selective bindinginteraction formed between a capture moiety and a binding partner of thecapture moiety attached to the insoluble support.

In some embodiments, the insoluble support comprises a bead or othersolid surface. For example, in some embodiments, the bead is aparamagnetic bead. The use of beads for isolation is well known in theart, and any suitable bead isolation method can be used with thetechniques described herein. In some embodiments, beads can be usefulfor isolation in that molecules of interest can be attached to thebeads, and the beads can be washed to remove solution components notattached to the beads, allowing for purification and isolation. In someembodiments, the beads can be separated from other components in thesolution based on properties such as size, density, or dielectric,ionic, and magnetic properties.

In some embodiments, the insoluble support is a magnetic bead. Use ofbeads allows the derivatized nucleic acid capture moiety to be separatedfrom a reaction mixture by centrifugation or filtration, or, in the caseof magnetic beads, by application of a magnetic field. In someembodiments, magnetic beads can be introduced, mixed, removed, andreleased into solution using magnetic fields. In some embodiments,processes utilizing magnetic beads may be automated. In someembodiments, the beads can be functionalized using well known chemistryto provide a surface having suitable functionalization for attaching abinding partner of a capture moiety. Derivatization of surfaces to allowbinding of the capture moiety is conventional in the art. For example,coating of surfaces with streptavidin allows binding of a biotinylatedcapture moiety. Coating of surfaces with streptavidin has been describedin, for example, U.S. Pat. No. 5,374,524 to Miller. In some embodiments,solid surfaces other than beads may be used. In some embodiments, thesolid surfaces can be planar surfaces, such as those used forhybridization microarrays, or the solid surfaces can be the packing of aseparation column.

In some embodiments, a binding partner of a capture moiety may beattached to an insoluble support before, simultaneous with, or afterbinding the capture moiety. In some embodiments, it may be preferable tocontact a capture moiety with a binding partner of the capture moietywhile both are in solution. In such embodiments, the capturemoiety:binding partner complex can then be immobilized on an insolublesupport by contacting the complex with an appropriately derivatizedsurface. Thus, in some embodiments, the molecule of interest may beisolated through a complex formed between a capture moiety attached tothe molecule of interest and a binding partner of the capture moiety.

In some embodiments, it may be desirable to attach the capture moiety toa nucleobase of a nucleotide. In this manner, the 3′ end remains free tobe optionally ligated to an adapter nucleic acid while the capturemoiety is available to be captured by a binding partner. In someembodiments, the capture moiety modified nucleotide comprises anucleobase selected from the group consisting of adenine, guanine,thymine, uracil, and cytosine, or a derivative thereof. For example, insome embodiments, the capture moiety modified nucleotide comprises anadenine nucleobase or derivative thereof. In some embodiments, thecapture moiety is covalently linked to the adenine nucleobase orderivative thereof at position 5, 6, 7 or 8. In some embodiments, thecapture moiety is covalently linked to the adenine nucleobase atposition 7. A numbering scheme for an adenine ring is depicted informula (II):

In some embodiments, it may be desirable to modify one or more positionson a nucleobase that is attached to a capture moiety. For example, insome embodiments, position 7 of the adenine nucleobase is a carbon atom.However, it should be appreciated that any atom capable of forming anadditional covalent bond (e.g., C, O, N, S, etc.) may be substitutedinto a position on a nucleobase suitable for attachment of a capturemoiety. In some embodiments, following capturing the adapter-ligatedfragments, the library is subjected to amplification to enrich targetnucleotide sequences.

Preparation of Nucleic Acids for Analysis

Aspects of the disclosure provide improved methods of determining thenucleotide sequence contiguous to a known target nucleotide sequence.Traditional sequencing methods generate sequence information randomly(e.g., “shotgun” sequencing) or between two known sequences which areused to design primers. In contrast, certain of the methods describedherein, in some embodiments, allow for determining the nucleotidesequence (e.g., sequencing) upstream or downstream of a single region ofknown sequence with a high level of specificity and sensitivity.

In some embodiments, the disclosure provides a method of enrichingspecific nucleotide sequences prior to determining the nucleotidesequence using a next-generation sequencing technology. In someembodiments, methods provided herein can relate to enriching samplescomprising deoxyribonucleic acid (DNA). In some embodiments, methodsprovided herein comprise: (a) adding one or more nucleotides to a 3′ endof a double-stranded nucleic acid comprising a target nucleotidesequence, wherein at least one (e.g., 1, 2, 3, 4, 5 or more) of the oneor more nucleotides is a capture moiety modified nucleotide; (b)ligating an adapter nucleic acid to the double-stranded nucleic acid towhich the capture moiety modified nucleotide has been added to produce aligation product, wherein a sequence of one or more nucleotides at a 3′end of the adapter nucleic acid is complementary with the one or morenucleotides added to the 3′ end of the double stranded nucleic acid instep (a); (c) capturing the ligation product by contacting the ligationproduct with a binding partner of a capture moiety of the capture moietymodified nucleotide; and (d) amplifying the ligation product bypolymerase chain reaction using a first target-specific primer thatspecifically anneals to the target nucleotide sequence and a firstadapter primer that specifically anneals to a complementary sequence ofthe adapter nucleic acid.

In some embodiments, the method further comprises: (e) amplifying anamplification product of step (d) by polymerase chain reaction using asecond adapter primer and a second target-specific primer. For example,FIG. 2 depicts a non-limiting process 200 by which this embodiment canproceed. Double-stranded nucleic acid 202 comprising a target nucleotidesequence is tailed by adding one or more capture moiety modifiednucleotides 204 to the 3′ ends (e.g., 1, 2, 3, 4, 5 or more capturemoiety modified nucleotides). The capture moiety labeled nucleic acid isligated with an adapter 206 to generate an adapter-ligated libraryfragment 208. The adapter-ligated fragment is isolated by introducing abinding partner of the capture moiety, the former of which is attachedto a magnetic support 210. Application of a magnetic field 212 isolatedadapter-ligated nucleic acids from unligated adapter. The capturedligation product is subjected to a first round of PCR using a firsttarget-specific primer 214 that specifically anneals to the targetnucleotide sequence and a first adapter primer 216 that specificallyanneals to a complementary sequence of the adapter nucleic acid. In thisway, the first adapter primer 216 primes off of the strand generated bythe first target-specific primer 214. A second round of PCR is conductedusing a second target-specific primer 218 and a second adapter primer220. As shown, the second target-specific primer 218 is nested relativeto the first target-specific primer 214. Also as shown, the secondtarget-specific primer is tailed with a 5′ region that does nothybridize with the target nucleotide sequence. In a similar fashion tothe first round of PCR, the second adapter primer 220 primes off of thestrand generated by the second target-specific primer 218. In thissecond round of PCR, an additional primer 222 is included that contains(i) a 3′ region that is identical to at least a portion of the tailed 5′region of the second target-specific primer 218 and (ii) a 5′ regionthat can contain additional elements useful for sequencing, such asindex or barcode sequences and primer binding sites. After the secondadapter primer 220 generates a sense strand from the complementarystrand generated by the second target-specific primer 218, theadditional primer 222 then primes off of the now complementary sequenceof the tailed region to generate the sequencing-ready product 224.

In some embodiments, the techniques described herein allow for theenrichment of target nucleotide sequences from a nucleic acid sample. Insome embodiments, the nucleic acid sample comprises genomic DNA. In someembodiments, the nucleic acid sample comprises cDNA. In someembodiments, cDNA may be prepared by conducting a randomly-primed firststrand synthesis reaction using a product of the randomly-primed firststrand synthesis reaction as a template, wherein the RNA preparationcomprises a target nucleotide sequence. In some embodiments, a nucleicacid sequencing library is prepared from an RNA preparation. Forexample, FIG. 3 generically depicts a process 300 by which adouble-stranded nucleic acid library fragment is prepared from an RNAtemplate.

As shown, an RNA template 302 is annealed with random primers 304 (e.g.,random hexamers) under conditions suitable for hybridization. Followingrandom priming, first strand cDNA synthesis is achieved bytemplate-dependent extension using a reverse transcriptase enzyme togenerate a DNA/RNA hybrid 306. The RNA strand of the DNA/RNA hybrid isenzymatically or chemically cleaved. The resulting fragments of RNA 308that remain hybridized to the DNA strand 310 serve as primers for secondstrand cDNA synthesis via the action of a polymerase. In someembodiments, inactivation of the polymerase following second strand cDNAsynthesis may be desirable, for example, to prevent 5′—>3′ and/or 3′—>5′exonuclease activity during end repair. Following second strand cDNAsynthesis, the double-stranded cDNA 312 is subjected to end repair togenerate blunt ended, 5′ phosphorylated cDNA 314. In some embodiments,SPRI cleanup (e.g., AMPure) is conducted following end repair. Assubsequent steps in the process may involve adding a capture moietymodified nucleotide to a 3′ end of the nucleic acid, it may bepreferable to remove any residual dNTPs in the sample. Thus, any cleanupmethod capable of removing dNTPs from solution are envisioned to besuitable in this technique. In some embodiments, a capture moietymodified nucleotide may be added and/or incorporated into a nucleic acidat an earlier step of preparing the nucleic acids (e.g., fragmentation,random or specific priming, first strand synthesis, second strandsynthesis, and/or end repair). In such embodiments, it may therefore bedesirable to perform a cleanup step preceding the step of adding and/orincorporating the capture moiety modified nucleotide.

The blunt ended, 5′ phosphorylated cDNA 314 is tailed with abiotin-labeled dATP 316 (biotin-11-ATP) comprising a thioate bond (e.g.,a phosphorothioate bond) at its 3′ ends and subjected to SPRI cleanupbefore being ligated with an adapter nucleic acid to generate anadapter-ligated library fragment 318. The inclusion of a crowding agent(20%) was shown to increase adapter ligation efficiency. Theadapter-ligated fragment 318 is captured by introducing astreptavidin-coated paramagnetic bead 320. Once the non-covalentbiotin-streptavidin complex has formed, application of a magnetic field322 captures the adapter-ligated nucleic acids to isolate the desiredproduct from unligated adapter.

As shown in FIG. 3 , in some embodiments, the captured adapter-ligatednucleic acid is subjected to a first round of PCR 324 in the form of abead-immobilized product. In yet other embodiments, as shown in FIG. 4 ,the captured adapter-ligated nucleic acid is eluted from theparamagnetic bead 320 prior to first round PCR 324. Elution of capturedadapter-ligated nucleic acids from the beads can be performed, by way ofexample and not limitation, using a chemical reagent and/or heat. Insome embodiments, the chemical reagent is a base (e.g., NaOH). In someembodiments, captured adapter-ligated nucleic acid is eluted with a lowconcentration (e.g., less than 1 M, less than 0.5 M, less than 0.1 M,less than 0.05 M, less than 0.01 M, less than 0.001 M, less than 0.0001M) of NaOH. In some embodiments, captured adapter-ligated nucleic acidis eluted with a low concentration of NaOH and heat.

The immobilized (e.g., as in FIG. 3 ) or eluted (e.g., as in FIG. 4 )adapter-ligated nucleic acid is subjected to a first round of PCR 324using a first gene-specific primer (“GSP1”) that specifically anneals tothe target nucleotide sequence and a first adapter primer (“P5_1”) thatspecifically anneals to a complementary sequence of the adapter nucleicacid. In this way, P5_1 primes off of the strand generated by GSP1. Asshown, in some embodiments, GSP1 (e.g., a first target-specific primer)is tailed with a 5′ region that does not hybridize with the targetnucleotide sequence. In some embodiments, a 5′ tail region can preventprimer dimers, e.g., by having a sequence content that minimizes theoccurrence of primer dimers. In some embodiments, GSP1 is not tailedwith the 5′ tailed region. As further shown in FIG. 3 , a second roundof PCR 326 is conducted using a second gene-specific primer (“GSP2”) anda second adapter primer (“P5_2”). As shown, GSP2 is nested relative toGSP1. Also as shown, GSP2 is tailed with a 5′ region that does nothybridize with the target nucleotide sequence. In a similar fashion tothe first round of PCR, P5_2 primes off of the strand generated by GSP2.In this second round of PCR, an additional primer (“SINGLE PRIMER”) isincluded that contains (i) a 3′ region that is identical to at least aportion of the tailed 5′ region of GSP2 and (ii) a 5′ region thatcontains additional elements useful for sequencing, such as a sequencingprimer binding site and a sample index. After P5_2 generates a sensestrand from the complementary strand generated by GSP2, the additionalprimer then primes off of the now complementary sequence of the GSP2tailed region to generate the sequencing-ready product 328.

Sample Purification

In some embodiments, target nucleic acids and/or amplification productsthereof can be isolated from enzymes, primers, or buffer componentsbefore and/or after any appropriate step of a method. Any suitablemethods for isolating nucleic acids may be used. In some embodiments,the isolation can comprise Solid Phase Reversible Immobilization (SPRI)cleanup. Methods for SPRI cleanup are well known in the art, e.g.,Agencourt AMPure XP-PCR Purification (Cat No. A63880, Beckman Coulter;Brea, CA). In some embodiments, enzymes can be inactivated by heattreatment. In some embodiments, unlabeled dNTPs are removed by enzymatictreatment.

In some embodiments, unhybridized primers can be removed from a nucleicacid preparation using appropriate methods (e.g., purification,digestion, etc.). In some embodiments, a nuclease (e.g., exonuclease I)is used to remove primers from a preparation. In some embodiments, suchnucleases are heat inactivated subsequent to primer digestion. Once thenucleases are inactivated, a further set of primers may be addedtogether with other appropriate components (e.g., enzymes, buffers) toperform a further amplification reaction.

In some embodiments, steps of the methods provided herein optionallycomprise an intervening sample purification step. In some embodiments, asample purification step comprises a wash step. In some embodiments, asample purification step comprises SPRI cleanup (e.g., AMPure). Forexample, a method of preparing nucleic acids for analysis can comprise:(a) preparing a cDNA by conducting a randomly-primed first strandsynthesis reaction using an RNA preparation as a template and a secondstrand synthesis reaction using a product of the randomly-primed firststrand synthesis reaction as a template, wherein the RNA preparationcomprises a target nucleotide sequence; (b) end repairing the cDNA toproduce a blunt-ended, double-stranded nucleic acid comprising thetarget nucleotide sequence; (c) immobilizing the blunt-ended,double-stranded nucleic acid on a paramagnetic substrate or surface; (d)washing the immobilized blunt-ended, double-stranded nucleic acid; (e)releasing the washed immobilized blunt-ended, double-stranded nucleicacid from the paramagnetic substrate or surface; (f) adding one or morenucleotides to the 3′ end of the released blunt-ended, double-strandednucleic acid; (g) ligating an adapter that comprises a ligatable duplexportion and an overhang sequence to the nucleic acid produced in step(f) to produce a ligation product, wherein the overhang sequence iscomplementary with the one or more nucleotides; (h) without washing theligation product, amplifying the ligation product by polymerase chainreaction using a first target-specific primer that specifically annealsto the target nucleotide sequence and a first adapter primer thatspecifically anneals to a complementary sequence of the adapter nucleicacid; (i) amplifying an amplification product of step (h) by polymerasechain reaction using a second adapter primer and a secondtarget-specific primer, wherein the second target-specific primer isnested relative to the first target-specific primer; (j) immobilizingthe amplification product of step (i) to a paramagnetic substrate orsurface; (k) washing the immobilized amplification product; and (1)releasing the washed immobilized amplification product from theparamagnetic substrate or surface. In some embodiments, steps of themethods provided herein optionally comprise adding one or morenucleotides to a nucleic acid, wherein at least one of the one or morenucleotides comprises a capture moiety, and capturing the nucleic acidvia an interaction between the capture moiety and a binding partner ofthe capture moiety. For example, a method of preparing nucleic acids foranalysis can comprise: (a) preparing a cDNA by conducting arandomly-primed first strand synthesis reaction using a nucleic acidpreparation as a template and a second strand synthesis reaction using aproduct of the randomly-primed first strand synthesis reaction as atemplate, wherein the nucleic acid preparation comprises a targetnucleotide sequence; (b) end repairing the cDNA to produce ablunt-ended, double-stranded nucleic acid comprising the targetnucleotide sequence; (c) washing the blunt-ended, double-strandednucleic acid; (d) adding one or more nucleotides to the 3′ end of thenucleic acid washed in step (c), optionally wherein at least one of theone or more nucleotides is a capture moiety modified nucleotide; (e)washing the nucleic acid produced in step (d); (f) ligating an adapternucleic acid that comprises a ligatable duplex portion and an overhangsequence to the nucleic acid washed in step (e) to produce a ligationproduct, wherein the overhang sequence is complementary with the one ormore nucleotides; (g) amplifying the ligation product by polymerasechain reaction using a first target-specific primer that specificallyanneals to the target nucleotide sequence and a first adapter primerthat specifically anneals to a complementary sequence of the adapternucleic acid; (h) amplifying an amplification product of step (g) bypolymerase chain reaction using a second adapter primer and a secondtarget-specific primer, wherein the second target-specific primer isnested relative to the first target-specific primer; and (j) washing theamplification product of step (h).

Nucleic Acid Adapter

As used herein, the term “nucleic acid adapter” or “adapter” refers to anucleic acid molecule that may be ligated to a nucleic acid comprising atarget nucleotide sequence to provide one or more elements useful duringamplification and/or sequencing of the target nucleotide sequence. Insome embodiments, an adapter is single-stranded. In some embodiments, anadapter is double-stranded. In some embodiments, a double-strandedadapter comprises a first ligatable duplex end and a second unpairedend. In some embodiments, an adapter comprises an amplification strandand a blocking strand. In some embodiments, the amplification strandcomprises a 5′ unpaired portion and a 3′ duplex portion. In someembodiments, the amplification strand further comprises a 3′ overhang.In some embodiments, the 3′ overhang is a 3′ T overhang. In someembodiments, the amplification strand comprises nucleotide sequencesidentical to a first and second adapter primer. In some embodiments, theblocking strand of the adapter comprises a 5′ duplex portion and anon-extendable 3′ portion. In some embodiments, the blocking strandfurther comprises a 3′ unpaired portion. In some embodiments, the duplexportions of the amplification strand and the blocking strand aresubstantially complementary and the duplex portion is of sufficientlength to remain in duplex form at the ligation temperature.

In some embodiments, the portion of the amplification strand thatcomprises a nucleotide sequence identical to a first and second adapterprimer can be comprised, at least in part, by the 5′ unpaired portion ofthe amplification strand.

In some embodiments, the adapter can have a “Y” shape, i.e., the secondunpaired end comprises a 5′ unpaired portion of an amplification strandand a 3′ portion of a blocking strand. The 3′ unpaired portion of theblocking strand can be shorter than, longer than, or equal in length tothe 5′ unpaired portion of the amplification strand. In someembodiments, the 3′ unpaired portion of the blocking strand can beshorter than the 5′ unpaired portion of the amplification strand.Y-shaped adapters have the advantage that the unpaired portion of theblocking strand will not be subject to 3′ extension during a PCRregimen.

In some embodiments, the blocking strand of the adapter can furthercomprise a 3′ unpaired portion that is not substantially complementaryto the 5′ unpaired portion of the amplification strand, wherein the 3′unpaired portion of the blocking strand is not substantiallycomplementary to or substantially identical to any of the primers. Insome embodiments, the blocking strand can further comprise a 3′ unpairedportion that does not specifically anneal to the 5′ unpaired portion ofthe amplification strand at the annealing temperature, wherein the 3′unpaired portion of the blocking strand will not specifically anneal toany of the primers or the complements thereof at the annealingtemperature. In some embodiments, an adapter nucleic acid comprises, ata minimum, a sample index sequence for multiplexing. However, in someembodiments, the adapter nucleic further comprises a random molecularbarcode.

Amplification

Aspects of the present disclosure relate to techniques that may compriseone or more rounds of amplification. In some embodiments, a first roundof amplification is conducted using a first target-specific primer and afirst adapter primer.

As used herein, a “first target-specific primer” is an oligonucleotidecomprising a nucleic acid sequence that can specifically anneal, undersuitable annealing conditions, to a target nucleotide sequence of atemplate nucleic acid. During amplification, the first target-specificprimer generates a strand that is complementary to its template, andthis complementary strand is capable of being hybridized with a firstadapter primer.

As used herein, a “first adapter primer” is an oligonucleotidecomprising a nucleic acid sequence that can specifically anneal, undersuitable annealing conditions, to a complementary sequence of an adapternucleic acid. As the first adapter primer is therefore identical to atleast a portion of the adapter, it anneals to the complementary strandgenerated by the first target specific-primer to allow amplification toproceed.

In some embodiments, in the first PCR amplification cycle of the firstamplification step, a first target-specific primer can specificallyanneal to a template strand of a nucleic acid comprising a targetnucleotide sequence. In some embodiments, depending upon the orientationwith which the first target-specific primer was designed, a sequenceupstream or downstream of the target nucleotide sequence will besynthesized as a strand complementary to the template strand. In someembodiments, if, during the extension phase of PCR, the 5′ end of atemplate strand terminates in a ligated adapter, the 3′ end of the newlysynthesized complementary strand will comprise sequence capable ofhybridizing with a first adapter primer. In subsequent PCR amplificationcycles, both the first target-specific primer and the first adapterprimer will be able to specifically anneal to the appropriate strands ofthe target nucleic acid sequence and the sequence between the knownnucleotide target sequence and the adapter can be amplified. In someembodiments, a second round of amplification is conducted using a secondtarget-specific primer and a second adapter primer.

As used herein, a “second target-specific primer” is an oligonucleotidecomprising a nucleic acid sequence that can specifically anneal, undersuitable annealing conditions, to a portion of the target nucleotidesequence comprised by the amplicon resulting from a precedingamplification step. During amplification, the second target-specificprimer generates a strand that is complementary to its template, andthis complementary strand is capable of being hybridized with a secondadapter primer.

As used herein, a “second adapter primer” is an oligonucleotidecomprising a nucleic acid sequence that can specifically anneal, undersuitable annealing conditions, to a complementary sequence of an adapternucleic acid. As the first adapter primer is therefore identical to atleast a portion of the adapter, it anneals to the complementary strandgenerated by the second target specific-primer to allow amplification toproceed.

In some embodiments, a second target-specific primer is nested relativeto a first target-specific primer. In some embodiments, the use ofnested adapter primers eliminates the possibility of producing finalamplicons that are amplifiable (e.g., during bridge PCR or emulsion PCR)but cannot be sequenced, a situation that can arise during hemi-nestedmethods. In other situations, hemi-nested approaches using a primeridentical to a sequencing primer can result in the carry-over ofundesired amplification products from the first PCR step to the secondPCR step and would ultimately yield artificial sequencing reads. In someembodiments, a second target-specific primer is nested with respect to afirst target-specific primer by at least 1 nucleotide, e.g., by 1, 2, 3,4, 5, 6, 7, 8, 9, 10, or more nucleotides. In some embodiments, a secondtarget-specific primer is nested with respect to a first target-specificprimer by about 5 nucleotides to about 10 nucleotides, by about 10nucleotides to about 15 nucleotides, by about 15 nucleotides to about 20nucleotides, or by about 20 nucleotides or more.

Among other aspects, techniques described herein may involve the use ofone or more nested primers. In some embodiments, the use of nestedprimers may reduce non-specific binding in PCR products due to theamplification of unexpected primer binding sites. As used herein, theterm “nested” is used to describe a positional relationship between theannealing site of a primer of a primer pair and the annealing site ofanother primer of another primer pair. For example, in some embodiments,a second primer is nested by 1, 2, 3 or more nucleotides relative to afirst primer, meaning that it binds to a site on the template strandthat is frame-shifted by 1, 2, 3 or more nucleotides.

In some embodiments, a second target-specific primer comprises a 3′portion that specifically anneals to a target nucleotide sequence and a5′ tail that does not anneal to the target nucleotide sequence. In someembodiments, the 5′ tail comprises a nucleic acid sequence that isidentical to a second sequencing primer. In some embodiments, multipleprimers (e.g., one or more target specific primers and/or one or moreadapter primers) present in a reaction can comprise identical 5′ tailsequence portions.

In some embodiments, a 5′ tail can be a GC-rich sequence. In someembodiments, a 5′ tail sequence may comprise at least 50% GC content, atleast 55% GC content, at least 60% GC content, at least 65% GC content,at least 70% GC content, at least 75% GC content, at least 80% GCcontent, or higher GC content. In some embodiments, a 5′ tail sequencemay comprise at least 60% GC content. In some embodiments, a 5′ tailsequence may comprise at least 65% GC content.

In some embodiments, a second round of amplification includes a secondtarget-specific primer comprising a 5′ tail, a first adapter primer, andan additional primer. In some embodiments, the additional primercomprises a 3′ portion that is identical to the 5′ tail of the secondtarget-specific primer. In some embodiments, the additional primer maycomprise additional sequences 5′ to the hybridization sequence that mayinclude barcode, index, adapter sequences, or sequencing primer sites.In some embodiments, the additional primer is a generic sequencingadapter/index primer.

In some embodiments, the first and second target-specific primers aresubstantially complementary to the same strand of the target nucleicacid. In some embodiments, the portions of the first and secondtarget-specific primers that specifically anneal to the known targetsequence can comprise a total of at least 20 unique bases of the knowntarget nucleotide sequence, e.g., 20 or more unique bases, 25 or moreunique bases, 30 or more unique bases, 35 or more unique bases, 40 ormore unique bases, or 50 or more unique bases. In some embodiments, theportions of the first and second target-specific primers thatspecifically anneal to the known target sequence can comprise a total ofat least 30 unique bases of the known target nucleotide sequence.

In some embodiments, the first adapter primer can comprise a nucleicacid sequence identical to about the 20 5′-most bases of theamplification strand of the adapter and the second adapter primer cancomprise a nucleic acid sequence identical to about 30 bases of theamplification strand of the adapter, with a 5′ base that is at least 1nucleotide 3′ of the 5′ terminus of the amplification strand.

In some embodiments, an adapter ligated nucleic acid (e.g., a ligationproduct) is minimal. In such embodiments, a first adapter primer may beused that contains a portion of the adapter nucleic sequence at its 3′end and then additional sequencer-important information at its 5′ end.In such embodiments, a second adapter primer may be used that contains,at its 3′ end, the 5′ end of the first adapter primer. In suchembodiments, the second adapter primer may also have a nucleotidesequence that permits sequencing at its 5′ end. In such embodiments, itis possible to produce, using PCR, a library that is sequencercompatible.

Primers

In some embodiments, primers (e.g., first and second target-specificprimers and first and second adapter primers) are designed such thatthey will specifically anneal to their complementary sequences at anannealing temperature of from about 61 to 72° C., e.g., from about 61 to69° C., from about 63 to 69° C., from about 63 to 67° C., from about 64to 66° C. In some embodiments, primers are designed such that they willspecifically anneal to their complementary sequences at an annealingtemperature of less than 72° C. In some embodiments, primers aredesigned such that they will specifically anneal to their complementarysequences at an annealing temperature of less than 70° C. In someembodiments, primers are designed such that they will specificallyanneal to their complementary sequences at an annealing temperature ofless than 68° C. In some embodiments, primers are designed such thatthey will specifically anneal to their complementary sequences at anannealing temperature of about 65° C. In some embodiments, systemsprovided herein are configured to alter vessel temperature (e.g., bycycling between different temperature ranges) to facilitate primerannealing.

In some embodiments, the portions of the target-specific primers thatspecifically anneal to the known target nucleotide sequence will annealspecifically at a temperature of about 61 to 72° C., e.g., from about 61to 69° C., from about 63 to 69° C., from about 63 to 67° C., from about64 to 66° C. In some embodiments, the portions of the target-specificprimers that specifically anneal to the known target nucleotide sequencewill anneal specifically at a temperature of about 65° C. in a PCRbuffer.

Nucleic Acid Extension, Amplification, and PCR

In some embodiments, methods described herein comprise an extensionregimen or step. In such embodiments, extension may proceed from one ormore hybridized random primers, using the nucleic acid molecules whichthe primers are hybridized to as templates. Extension steps aredescribed herein. In some embodiments, one or more random primers canhybridize to substantially all of the nucleic acids in a sample, many ofwhich may not comprise a target nucleotide sequence. Accordingly, insome embodiments, extension of random primers may occur due tohybridization with templates that do not comprise a target nucleotidesequence.

In some embodiments, methods described herein may involve a polymerasechain reaction (PCR) amplification regimen, involving one or moreamplification cycles. Amplification steps of the methods describedherein can each comprise a PCR amplification regimen, i.e., a set ofpolymerase chain reaction (PCR) amplification cycles. As used herein,the term “amplification regimen” refers to a process of specificallyamplifying (increasing the abundance of) a nucleic acid of interest. Insome embodiments, exponential amplification occurs when products of aprevious polymerase extension serve as templates for successive roundsof extension. In some embodiments, a PCR amplification regimen accordingto methods disclosed herein may comprise at least one, and in some casesat least 5 or more iterative cycles. In some embodiments, each iterativecycle comprises steps of: 1) strand separation (e.g., thermaldenaturation); 2) oligonucleotide primer annealing to templatemolecules; and 3) nucleic acid polymerase extension of the annealedprimers. In should be appreciated that any suitable conditions and timesinvolved in each of these steps may be used. In some embodiments,conditions and times selected may depend on the length, sequencecontent, melting temperature, secondary structural features, or otherfactors relating to the nucleic acid template and/or primers used in thereaction. In some embodiments, an amplification regimen according tomethods described herein is performed in a thermal cycler, many of whichare commercially available. In some embodiments, methods describedherein can comprise linear amplification. For example, in someembodiments, amplification steps performed using nested primers may beperformed using linear amplification. In some embodiments, amplificationmay be conducted using nucleic acid sequence-based amplification(NASBA). For example, in some embodiments, amplification comprises aT7-mediated NASBA reaction.

In some embodiments, a nucleic acid extension reaction involves the useof a nucleic acid polymerase. As used herein, the phrase “nucleic acidpolymerase” refers to an enzyme that catalyzes the template-dependentpolymerization of nucleoside triphosphates to form primer extensionproducts that are complementary to the template nucleic acid sequence. Anucleic acid polymerase enzyme initiates synthesis at the 3′ end of anannealed primer and proceeds in the direction toward the 5′ end of thetemplate. Numerous nucleic acid polymerases are known in the art and arecommercially available. One group of nucleic acid polymerases arethermostable, i.e., they retain function after being subjected totemperatures sufficient to denature annealed strands of complementarynucleic acids, e.g., 94° C. or sometimes higher. A non-limiting exampleof a protocol for amplification involves using a polymerase (e.g.,Phoenix Taq, VeraSeq) under the following conditions: 98° C. for 30 s,followed by 14-22 cycles comprising melting at 98° C. for 10 s, followedby annealing at 68° C. for 30 s, followed by extension at 72° C. for 3min, followed by holding of the reaction at 4° C. However, otherappropriate reaction conditions may be used. In some embodiments,annealing/extension temperatures may be adjusted to account fordifferences in salt concentration (e.g., 3° C. higher to higher saltconcentrations). In some embodiments, slowing the ramp rate (e.g., 1°C./s, 0.5° C./s, 0.28° C./s, 0.1° C./s or slower), for example, from 98°C. to 65° C., improves primer performance and coverage uniformity inhighly multiplexed samples. In some embodiments, systems provided hereinare configured to alter vessel temperature (e.g., by cycling betweendifferent temperature ranges, having controlled ramp up or down rates)to facilitate amplification.

In some embodiments, a nucleic acid polymerase is used under conditionsin which the enzyme performs a template-dependent extension. In someembodiments, the nucleic acid polymerase is DNA polymerase I, Taqpolymerase, Phoenix Taq polymerase, Phusion polymerase, T4 polymerase,T7 polymerase, Klenow fragment, Klenow exo-, phi29 polymerase, AMVreverse transcriptase, M-MuLV reverse transcriptase. HIV-1 reversetranscriptase, VeraSeq ULtra polymerase, VeraSeq HF 2.0 polymerase,EnzScript, or another appropriate polymerase. In some embodiments, anucleic acid polymerase is not a reverse transcriptase. In someembodiments, a nucleic acid polymerase acts on a DNA template. In someembodiments, the nucleic acid polymerase acts on an RNA template. Insome embodiments, an extension reaction involves reverse transcriptionperformed on an RNA to produce a complementary DNA molecule(RNA-dependent DNA polymerase activity). In some embodiments, a reversetranscriptase is a mouse moloney murine leukemia virus (M-MLV)polymerase, AMV reverse transcriptase, RSV reverse transcriptase, HIV-1reverse transcriptase, HIV-2 reverse transcriptase, or anotherappropriate reverse transcriptase.

In some embodiments, a nucleic acid amplification reaction involvescycles including a strand separation step generally involving heating ofthe reaction mixture. As used herein, the term “strand separation” or“separating the strands” means treatment of a nucleic acid sample suchthat complementary double-stranded molecules are separated into twosingle strands available for annealing to an oligonucleotide primer. Insome embodiments, strand separation according to methods describedherein is achieved by heating the nucleic acid sample above its meltingtemperature (T_(m)). In some embodiments, for a sample containingnucleic acid molecules in a reaction preparation suitable for a nucleicacid polymerase, heating to 94° C. is sufficient to achieve strandseparation. In some embodiments, a suitable reaction preparationcontains one or more salts (e.g., 1 to 100 mM KCl, 0.1 to 10 mM MgCl₂),at least one buffering agent (e.g., 1 to 20 mM Tris-HCl), and a carrier(e.g., 0.01 to 0.5% BSA). A non-limiting example of a suitable buffercomprises 50 mM KCl, 10 mM Tris-HCl (pH 8.8 at 25° C.), 0.5 to 3 mMMgCl₂, and 0.1% BSA. A further non-limiting example of a suitable buffercomprises 50 mM KCl, 10 mM Tris-HCl (pH 8.8 at 25° C.), 0.5 to 5 mM(e.g., approximately 0.5 mM, approximately 1 mM, approximately 2 mM,approximately 3 mM, approximately 4 mM, approximately 5 mM) MgCl₂, and0.1% BSA.

In some embodiments, a nucleic acid amplification involves annealingprimers to nucleic acid templates having a strands characteristic of atarget nucleic acid. In some embodiments, a strand of a target nucleicacid can serve as a template nucleic acid. As used herein, the term“anneal” refers to the formation of one or more complementary base pairsbetween two nucleic acids. In some embodiments, annealing involves twocomplementary or substantially complementary nucleic acid strandshybridizing together. In some embodiments, in the context of anextension reaction, annealing involves the hybridization of primer to atemplate such that a primer extension substrate for a template-dependentpolymerase enzyme is formed. In some embodiments, conditions forannealing (e.g., between a primer and nucleic acid template) may varybased of the length and sequence of a primer. In some embodiments,conditions for annealing are based upon a T_(m) (e.g., a calculatedT_(m)) of a primer. In some embodiments, an annealing step of anextension regimen involves reducing the temperature following a strandseparation step to a temperature based on the T_(m) (e.g., a calculatedT_(m)) for a primer, for a time sufficient to permit such annealing. Insome embodiments, a T_(m) can be determined using any of a number ofalgorithms (e.g., OLIGO™ (Molecular Biology Insights Inc. Colorado)primer design software and VENTRO NTI™ (Invitrogen, Inc. California)primer design software and programs available on the internet, includingPrimer3, Oligo Calculator, and NetPrimer (Premier Biosoft; Palo Alto,CA; and freely available on the world wide web (e.g., atpremierbiosoft.com/netprimer/netprlaunch/Help/xnetprlaunch.html)). Insome embodiments, the T_(m) of a primer can be calculated using thefollowing formula, which is used by NetPrimer software and is describedin more detail in Freier, et al. PNAS 1986 83:9373-9377 which isincorporated by reference herein in its entirety.T _(m) =ΔH/(ΔS+R*ln(C/4))+16.6 log([K ⁺]/(1+0.7[K ⁺]))−273.15wherein: ΔH is enthalpy for helix formation; ΔS is entropy for helixformation; R is molar gas constant (1.987 cal/° C.*mol); C is thenucleic acid concentration; and [K⁺] is salt concentration. For mostamplification regimens, the annealing temperature is selected to beabout 5° C. below the predicted T_(m), although temperatures closer toand above the T_(m) (e.g., between 1° C. and 5° C. below the predictedT_(m) or between 1° C. and 5° C. above the predicted T_(m)) can be used,as can, for example, temperatures more than 5° C. below the predictedT_(m) (e.g., 6° C. below, 8° C. below, 10° C. below or lower). In someembodiments, the closer an annealing temperature is to the T_(m), themore specific is the annealing. In some embodiments, the time used forprimer annealing during an extension reaction (e.g., within the contextof a PCR amplification regimen) is determined based, at least in part,upon the volume of the reaction (e.g., with larger volumes involvinglonger times). In some embodiments, the time used for primer annealingduring an extension reaction (e.g., within the context of a PCRamplification regimen) is determined based, at least in part, uponprimer and template concentrations (e.g., with higher relativeconcentrations of primer to template involving less time than lowerrelative concentrations). In some embodiments, depending upon volume andrelative primer/template concentration, primer annealing steps in anextension reaction (e.g., within the context of an amplificationregimen) can be in the range of 1 second to 5 minutes, 10 seconds to 2minutes, or 30 seconds to 2 minutes. As used herein, “substantiallyanneal” refers to an extent to which complementary base pairs formbetween two nucleic acids that, when used in the context of a PCRamplification regimen, is sufficient to produce a detectable level of aspecifically amplified product.

As used herein, the term “polymerase extension” refers totemplate-dependent addition of at least one complementary nucleotide, bya nucleic acid polymerase, to the 3′ end of a primer that is annealed toa nucleic acid template. In some embodiments, polymerase extension addsmore than one nucleotide, e.g., up to and including nucleotidescorresponding to the full length of the template. In some embodiments,conditions for polymerase extension are based, at least in part, on theidentity of the polymerase used. In some embodiments, the temperatureused for polymerase extension is based upon the known activityproperties of the enzyme. In some embodiments, in which annealingtemperatures are below the optimal temperatures for the enzyme, it maybe acceptable to use a lower extension temperature. In some embodiments,enzymes may retain at least partial activity below their optimalextension temperatures. In some embodiments, a polymerase extension(e.g., performed with thermostable polymerases such as Taq polymeraseand variants thereof) is performed at 65° C. to 75° C. or 68° C. to 72°C. In some embodiments, methods provided herein involve polymeraseextension of primers that are annealed to nucleic acid templates at eachcycle of a PCR amplification regimen. In some embodiments, a polymeraseextension is performed using a polymerase that has relatively strongstrand displacement activity. In some embodiments, polymerases havingstrong strand displacement are useful for preparing nucleic acids forpurposes of detecting fusions (e.g., 5′ fusions). In some embodiments,polymerases having 5′-3′ exonuclease activity (e.g., Taq polymerase) areuseful for producing long library fragments.

In some embodiments, primer extension is performed under conditions thatpermit the extension of annealed oligonucleotide primers. As usedherein, the term “conditions that permit the extension of an annealedoligonucleotide such that extension products are generated” refers tothe set of conditions (e.g., temperature, salt and co-factorconcentrations, pH, and enzyme concentration) under which a nucleic acidpolymerase catalyzes primer extension. In some embodiments, suchconditions are based, at least in part, on the nucleic acid polymerasebeing used. In some embodiments, a polymerase may perform a primerextension reaction in a suitable reaction preparation.

In some embodiments, a suitable reaction preparation contains one ormore salts (e.g., 1 to 100 mM KCl, 0.1 to 10 mM MgCl₂), at least onebuffering agent (e.g., 1 to 20 mM Tris-HCl), a carrier (e.g., 0.01 to0.5% BSA), and one or more NTPs (e.g., 10 to 200 μM of each of dATP,dTTP, dCTP, and dGTP). A non-limiting set of conditions is 50 mM KCl, 10mM Tris-HCl (pH 8.8 at 25° C.), 0.5 to 3 mM MgCl₂, 200 μM each dNTP, and0.1% BSA at 72° C., under which a polymerase (e.g., Taq polymerase)catalyzes primer extension.

In some embodiments, a suitable reaction preparation contains one ormore salts (e.g., 1 to 100 mM KCl, 0.5 to 5 mM MgCl₂), at least onebuffering agent (e.g., 1 to 20 mM Tris-HCl), a carrier (e.g., 0.01 to0.5% BSA), and one or more NTPs (e.g., 50 to 350 μM of each of dATP,dTTP, dCTP, and dGTP). A non-limiting set of conditions is 50 mM KCl, 10mM Tris-HCl (pH 8.8 at 25° C.), 3 mM MgCl₂, 200 μM each dNTP, and 0.1%BSA at 72° C., under which a polymerase (e.g., Taq polymerase) catalyzesprimer extension. A further non-limiting set of conditions is 50 mM KCl,10 mM Tris-HCl (pH 8.8 at 25° C.), 3 mM MgCl₂, 266 μM dATP, 200 μM dCTP,133 μM dGTP, 200 μM dTTP, and 0.1% BSA at 72° C., under which apolymerase (e.g., Taq polymerase) catalyzes primer extension.

In some embodiments, conditions for initiation and extension may includethe presence of one, two, three or four different deoxyribonucleosidetriphosphates (e.g., selected from dATP, dTTP, dCTP, and dGTP) and apolymerization-inducing agent such as DNA polymerase or reversetranscriptase, in a suitable buffer. In some embodiments, a “buffer” mayinclude solvents (e.g., aqueous solvents) plus appropriate cofactors andreagents which affect pH, ionic strength, etc. In some embodiments, thetwo, three or four different deoxyribonucleoside triphosphates arepresent in equimolar, or approximately equimolar, concentrations. Insome embodiments, the two, three or four different deoxyribonucleosidetriphosphates are present in different concentrations, which have beenexperimentally determined to be suitable to a particular implementationof the technology.

In some embodiments, nucleic acid amplification involves up to 5, up to10, up to 20, up to 30, up to 40 or more rounds (cycles) ofamplification. In some embodiments, nucleic acid amplification maycomprise a set of cycles of a PCR amplification regimen from 5 cycles to20 cycles in length. In some embodiments, an amplification step maycomprise a set of cycles of a PCR amplification regimen from 10 cyclesto 20 cycles in length. In some embodiments, each amplification step cancomprise a set of cycles of a PCR amplification regimen from 12 cyclesto 16 cycles in length. In some embodiments, an annealing temperaturecan be less than 70° C. In some embodiments, an annealing temperaturecan be less than 72° C. In some embodiments, an annealing temperaturecan be about 65° C. In some embodiments, an annealing temperature can befrom about 61 to about 72° C.

In various embodiments, methods and compositions described herein relateto performing a PCR amplification regimen with one or more of the typesof primers described herein. As used herein, “primer” refers to anoligonucleotide capable of specifically annealing to a nucleic acidtemplate and providing a 3′ end that serves as a substrate for atemplate-dependent polymerase to produce an extension product which iscomplementary to the template. In some embodiments, a primer issingle-stranded, such that the primer and its complement can anneal toform two strands. Primers according to methods and compositionsdescribed herein may comprise a hybridization sequence (e.g., a sequencethat anneals with a nucleic acid template) that is less than or equal to300 nucleotides in length, e.g., less than or equal to 300, or 250, or200, or 150, or 100, or 90, or 80, or 70, or 60, or 50, or 40, or 30 orfewer, or 20 or fewer, or 15 or fewer, but at least 6 nucleotides inlength. In some embodiments, a hybridization sequence of a primer may be6 to 50 nucleotides in length, 6 to 35 nucleotides in length, 6 to 20nucleotides in length, 10 to 25 nucleotides in length.

Any suitable method may be used for synthesizing oligonucleotides andprimers. In some embodiments, commercial sources offer oligonucleotidesynthesis services suitable for providing primers for use in methods andcompositions described herein (e.g., INVITROGEN™ Custom DNA Oligos (LifeTechnologies, Grand Island, NY) or custom DNA Oligos from Integrated DNATechnologies (Coralville, IA)).

Target Nucleic Acid

As used herein, the terms “target nucleic acid” and “nucleic acidcomprising a target nucleotide sequence” refer to a nucleic acidmolecule of interest (e.g., a nucleic acid to be prepared for analysis).In some embodiments, a target nucleic acid comprises both a targetnucleotide sequence (e.g., a known or predetermined nucleotide sequence)and an adjacent nucleotide sequence that is to be determined (which maybe referred to as an unknown sequence). A target nucleic acid can be ofany appropriate length. In some embodiments, a target nucleic acid isdouble-stranded. In some embodiments, a target nucleic acid is DNA.

In some embodiments, a target nucleic acid comprises genomic orchromosomal DNA (gDNA). In some embodiments, a target nucleic acidcomprises complementary DNA (cDNA). In some embodiments, a targetnucleic acid is single-stranded. In some embodiments, a target nucleicacid comprises RNA (e.g., mRNA, rRNA, tRNA, cfDNA, cfRNA, longnon-coding RNA, microRNA).

Many of the sequencing methods suitable for use in the methods describedherein provide sequencing runs with optimal read lengths of tens tohundreds of nucleotide bases (e.g., Ion Torrent technology can produceread lengths of 200-400 bp). Target nucleic acids comprised, forexample, by genomic DNA or mRNA, can be comprised by nucleic acidmolecules which are substantially longer than this optimal read length.In order for the amplified nucleic acid portion resulting from thesecond amplification step to be of a suitable length (e.g., up to 100bp, 200 bp, 300 bp, 400 bp, 500 bp, 1 kb, 2 kb) for use in a particularsequencing technology, the average distance between the known targetnucleotide sequence and an end of the target nucleic acid to which theadapter can be ligated should be as close to the optimal read length ofthe selected technology as possible. For example, if the optimalread-length of a given sequencing technology is 200 bp, then the nucleicacid molecules amplified in accordance with the methods described hereinshould have an average length of about 400 bp or less. However, itshould be appreciated that, in some embodiments, techniques describedherein may be implemented when nucleic acid molecules exceed 400 bp inlength. For example, in some embodiments, nucleic acid fragments can beapproximately 400 or more nucleotides, 500 or more nucleotides, 600 ormore nucleotides, 700 or more nucleotides, 800 or more nucleotides, 900or more nucleotides, 1000 or more nucleotides, 1500 or more nucleotides,2000 or more nucleotides, 2500 or more nucleotides, 3000 or morenucleotides, 4000 or more nucleotides, 5000 or more nucleotides, 10000or more nucleotides.

Target nucleic acids comprised by, e.g., genomic DNA or mRNA, can besheared, e.g., mechanically or enzymatically sheared, to generatefragments of any desired size. Non-limiting examples of mechanicalshearing processes include sonication, nebulization, and AFA™ shearingtechnology available from Covaris (Woburn, MA). In some embodiments, atarget nucleic acid comprised by genomic DNA can be mechanically shearedby sonication.

In some embodiments, when the target nucleic acid is comprised by RNA,the sample can be subjected to a reverse transcriptase regimen togenerate a DNA template. In some embodiments, the DNA template can thenbe sheared. In some embodiments, the DNA template is not sheared. Forexample, in some embodiments, the concentration of primers used during areverse transcriptase regimen can be adjusted such that the product cDNAis of an appropriate “fragmented” length. In some embodiments, targetRNA can be sheared before performing the reverse transcriptase regimen.In some embodiments, a sample comprising target RNA can be used in themethods described herein using total nucleic acids extracted from eitherfresh or degraded specimens; without the need of genomic DNA removal forcDNA sequencing; without the need of ribosomal RNA depletion for cDNAsequencing; without the need of mechanical or enzymatic shearing in anyof the steps; by subjecting the RNA for double-stranded cDNA synthesisusing random hexamers; and by subjecting the nucleic acid to end-repair,phosphorylation, and adenylation.

In some embodiments, a target nucleotide sequence can be comprised by agene rearrangement. The methods described herein are suited fordetermining the presence and/or identity of a gene rearrangement as theidentity of only one half of the gene rearrangement must be previouslyknown (i.e., the half of the gene rearrangement which is to be targetedby the gene-specific primers). In some embodiments, the generearrangement can comprise an oncogene. In some embodiments, the generearrangement can comprise a fusion oncogene. In some embodiments, thegene rearrangement can comprise a V(D)J recombination product.

As used herein, the term “known target nucleotide sequence” or “targetnucleotide sequence” refers to a portion of a target nucleic acid forwhich the sequence (e.g., the identity and order of the nucleotide basesof the nucleic acid) is known. For example, in some embodiments, a knowntarget nucleotide sequence is a nucleotide sequence of a nucleic acidthat is known or that has been determined in advance of an interrogationof an adjacent unknown sequence of the nucleic acid. A known targetnucleotide sequence can be of any appropriate length.

In some embodiments, a target nucleotide sequence (e.g., a known targetnucleotide sequence) has a length of 10 or more nucleotides, 30 or morenucleotides, 40 or more nucleotides, 50 or more nucleotides, 100 or morenucleotides, 200 or more nucleotides, 300 or more nucleotides, 400 ormore nucleotides, 500 or more nucleotides, 600 or more nucleotides, 700or more nucleotides, 800 or more nucleotides, 900 or more nucleotides,1000 or more nucleotides, 1500 or more nucleotides, 2000 or morenucleotides, 2500 or more nucleotides, 3000 or more nucleotides, 4000 ormore nucleotides, 5000 or more nucleotides, 10000 or more nucleotides.In some embodiments, a target nucleotide sequence (e.g., a known targetnucleotide sequence) has a length in the range of 10 to 100 nucleotides,10 to 500 nucleotides, 10 to 1000 nucleotides, 100 to 500 nucleotides,100 to 1000 nucleotides, 500 to 1000 nucleotides, 500 to 5000nucleotides.

In some embodiments, methods are provided herein for determiningsequences of contiguous (or adjacent) portions of a nucleic acid. Asused herein, the term “nucleotide sequence contiguous to” refers to anucleotide sequence of a nucleic acid molecule (e.g., a target nucleicacid) that is immediately upstream or downstream of another nucleotidesequence (e.g., a known nucleotide sequence). In some embodiments, anucleotide sequence contiguous to a known target nucleotide sequence maybe of any appropriate length. In some embodiments, a nucleotide sequencecontiguous to a known target nucleotide sequence comprises 1 kb or lessof nucleotide sequence, e.g., 1 kb or less of nucleotide sequence, 750bp or less of nucleotide sequence, 500 bp or less of nucleotidesequence, 400 bp or less of nucleotide sequence, 300 bp or less ofnucleotide sequence, 200 bp or less of nucleotide sequence, 100 bp orless of nucleotide sequence. In some embodiments, in which a samplecomprises different target nucleic acids comprising a known targetnucleotide sequence (e.g., a cell in which a known target nucleotidesequence occurs multiple times in its genome, or on separate,non-identical chromosomes), there may be multiple sequences whichcomprise “a nucleotide sequence contiguous to” the known targetnucleotide sequence. As used herein, the term “determining a (or the)nucleotide sequence,” refers to determining the identity and relativepositions of the nucleotide bases of a nucleic acid.

In some embodiments, a known target nucleic acid can contain a fusionsequence resulting from a gene rearrangement. In some embodiments,methods described herein are suited for determining the presence and/oridentity of a gene rearrangement. In some embodiments, the identity ofone portion of a gene rearrangement is previously known (e.g., theportion of a gene rearrangement that is to be targeted by thegene-specific primers) and the sequence of the other portion may bedetermined using methods disclosed herein. In some embodiments, a generearrangement can involve an oncogene. In some embodiments, a generearrangement can comprise a fusion oncogene.

Molecular Barcodes and Index Sequences

In some embodiments, primers and/or adapters may contain additionalsequences such as an identifier sequence (e.g., a barcode, an index),sequencing primer hybridization sequences (e.g., Rd 1), and adaptersequences. In some embodiments the adapter sequences are sequences usedwith a next generation sequencing system. In some embodiments, theadapter sequences are P5 and P7 sequences for Illumina-based sequencingtechnology. In some embodiments, the adapter sequence are P1 and Acompatible with Ion Torrent sequencing technology.

In some embodiments, as used herein, “barcode,” “molecular barcode,” and“molecular barcode tag” may be used interchangeably, and generally referto a region of an adapter nucleic acid that is useful as an identifierfor the specific nucleic acid to which it is ligated. In someembodiments, a molecular barcode comprises a randomized nucleic acidsequence that provides a unique identifier for the nucleic acid to whichit is ligated. In some embodiments, a molecular barcode may be used toidentify unique fragments and “de-duplicate” the sequencing reads from asample. In some embodiments, a molecular barcode may be used to identifyand remove PCR duplicates. In some embodiments, a molecular barcode maybe 2 to 25 nucleotides in length, 2 to 15 nucleotides in length, 2 to 10nucleotides in length, 2 to 6 nucleotides in length. In someembodiments, a molecular barcode comprises at least 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or atleast 25 nucleotides. In some embodiments, a molecular barcode comprises8 nucleotides.

In some embodiments, as used herein, “index,” “index sequence,” “indexregion,” and “sample index” may be used interchangeably, and generallyrefer to a region of an adapter nucleic acid that is useful as anidentifier for the population to which the ligated nucleic acid belongs.In some embodiments, an index comprises a fixed nucleic acid sequencethat may be used to identify a collection of sequences belonging to acommon library. For example, an index may be used to identify a samplethat corresponds to a nucleic acid. In some embodiments, an index may beused, for example, as a source identifier, location identifier, date ortime identifier (e.g., date or time of sampling or processing), or otheridentifier of a nucleic acid relating to a shared or common property(e.g., common among other nucleic acids of a library). In someembodiments, such index sequences are useful for identifying differentaspects of a nucleic acid that are present in a population of nucleicacids. In some embodiments, index sequences may provide a source orlocation identifier for a target nucleic acid. For example, an indexsequence may serve to identify a patient from whom a nucleic acid isobtained. In some embodiments, index sequences enable sequencing ofmultiple different samples on a single reaction (e.g., performed in asingle flow cell). In some embodiments, an index sequence can be used toorientate a sequence imager for purposes of detecting individualsequencing reactions. In some embodiments, an index sequence may be 2 to25 nucleotides in length, 2 to 15 nucleotides in length, 2 to 10nucleotides in length, 2 to 6 nucleotides in length. In someembodiments, an index comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or at least 25nucleotides.

In some embodiments, when a population of tailed random primers is usedin accordance with methods described herein, multiple distinguishableamplification products can be present after amplification. In someembodiments, because tailed random primers hybridize at variouspositions throughout nucleic acid molecules of a sample, a set oftarget-specific primers can hybridize (and amplify) the extensionproducts created by more than 1 hybridization event, e.g., one tailedrandom primer may hybridize at a first distance (e.g., 100 nucleotides)from a target-specific primer hybridization site, and another tailedrandom primer can hybridize at a second distance (e.g., 200 nucleotides)from a target-specific primer hybridization site, thereby resulting intwo amplification products (e.g., a first amplification productcomprising about 100 bp and a second amplification product comprisingabout 200 bp). In some embodiments, these multiple amplificationproducts can each be sequenced using next generation sequencingtechnology. In some embodiments, sequencing of these multipleamplification products is advantageous because it provides multipleoverlapping sequence reads that can be compared with one another todetect sequence errors introduced during amplification or sequencingprocesses. In some embodiments, individual amplification products (e.g.,derived from a single molecule) can be aligned and where they differ inthe sequence present at a particular base, an artifact or error of PCRand/or sequencing may be present.

DNA Shearing/Fragmentation

The nucleic acid molecules described herein can be sheared (e.g.,mechanically or enzymatically sheared, sheared via nebulizer) togenerate fragments of any desired size. Non-limiting examples ofmechanical shearing processes include sonication, nebulization, and AFA™shearing technology available from Covaris (Woburn, MA). In someembodiments, a nucleic acid can be mechanically sheared by sonication.In some embodiments, a target nucleic acid is not sheared or digested.In some embodiments, nucleic acid products of preparative steps (e.g.,extension products, amplification products) are not sheared orenzymatically digested.

In some embodiments, when a target nucleotide sequence comprises RNA,the sample can be subjected to a reverse transcriptase regimen togenerate a DNA template and the DNA template can then be sheared. Insome embodiments, target RNA can be sheared before performing a reversetranscriptase regimen. In some embodiments, a sample comprising targetRNA can be used in methods described herein using total nucleic acidsextracted from either fresh or degraded specimens; without the need ofgenomic DNA removal for cDNA sequencing; without the need of ribosomalRNA depletion for cDNA sequencing; without the need of mechanical orenzymatic shearing in any of the steps; by subjecting the RNA fordouble-stranded cDNA synthesis using random hexamers.

Sequencing

In some aspects, the technology described herein relates to methods ofenriching nucleic acid samples for oligonucleotide sequencing. In someembodiments, the sequencing can be performed by a next-generationsequencing method. As used herein, “next-generation sequencing” refersto oligonucleotide sequencing technologies that have the capacity tosequence oligonucleotides at speeds above those possible withconventional sequencing methods (e.g., Sanger sequencing), due toperforming and reading out thousands to millions of sequencing reactionsin parallel. Non-limiting examples of next-generation sequencingmethods/platforms include Massively Parallel Signature Sequencing (LynxTherapeutics); 454 pyro-sequencing (454 Life Sciences/RocheDiagnostics); solid-phase, reversible dye-terminator sequencing(Solexa/Illumina); SOLiD technology (Applied Biosystems); Ionsemiconductor sequencing (ION Torrent); DNA nanoball sequencing(Complete Genomics); and technologies available from PacificBiosciences, Intelligent Biosystems, and Oxford Nanopore Technologies.In some embodiments, the sequencing primers can comprise portionscompatible with the selected next-generation sequencing method.Next-generation sequencing technologies and the constraints and designparameters of associated sequencing primers are well known in the art(see, e.g., Shendure, et al., “Next-generation DNA sequencing,” Nature,2008, vol. 26, No. 10, 1135-1145; Mardis, “The impact of next-generationsequencing technology on genetics,” Trends in Genetics, 2007, vol. 24,No. 3, pp. 133-141; Su, et al., “Next-generation sequencing and itsapplications in molecular diagnostics” Expert Rev Mol Diagn, 2011,11(3):333-43; Zhang et al., “The impact of next-generation sequencing ongenomics”, J Genet Genomics, 2011, 38(3):95-109; (Nyren, P. et al. AnalBiochem 208: 17175 (1993); Bentley, D. R. Curr Opin Genet Dev 16:545-52(2006); Strausberg, R. L., et al. Drug Disc Today 13:569-77 (2008); U.S.Pat. Nos. 7,282,337; 7,279,563; 7,226,720; 7,220,549; 7,169,560;6,818,395; 6,911,345; US Pub. Nos. 2006/0252077; 2007/0070349; and20070070349; which are incorporated by reference herein in theirentireties).

In some embodiments, the sequencing step relics upon the use of a firstand second sequencing primer. In some embodiments, the first and secondsequencing primers are selected to be compatible with a next-generationsequencing method as described herein.

Methods of aligning sequencing reads to known sequence databases ofgenomic and/or cDNA sequences are well known in the art, and software iscommercially available for this process. In some embodiments, reads(less the sequencing primer and/or adapter nucleotide sequence) which donot map, in their entirety, to wild-type sequence databases can begenomic rearrangements or large indel mutations. In some embodiments,reads (less the sequencing primer and/or adapter nucleotide sequence)comprising sequences which map to multiple locations in the genome canbe genomic rearrangements. In some embodiments, a de novo assembly ofreads overlapping into contiguous sequences, or “contigs,” may be builtand utilized in the alignment of sequencing reads. In some embodiments,a hot spot reference may be utilized that does not rely on a publiclyaccessible genomics database.

Samples

In some embodiments, a nucleic acid (e.g., target nucleic acid, nucleicacid comprising a target nucleotide sequence) is present in or obtainedfrom an appropriate sample (e.g., a food sample, environmental sample,biological sample e.g., blood sample, etc.). In some embodiments, thetarget nucleic acid is a biological sample obtained from a subject. Insome embodiments a sample can be a diagnostic sample obtained from asubject. In some embodiments, a sample can further comprise proteins,cells, fluids, biological fluids, preservatives, and/or othersubstances. By way of non-limiting example, a sample can be a cheekswab, blood, serum, plasma, sputum, cerebrospinal fluid, urine, tears,alveolar isolates, pleural fluid, pericardial fluid, cyst fluid, tumortissue, tissue, a biopsy, saliva, an aspirate, or combinations thereof.In some embodiments, a sample can be obtained by resection or biopsy.

In some embodiments, the sample can be obtained from a subject in needof treatment for a disease associated with a genetic alteration, e.g.,cancer or a hereditary disease. In some embodiments, a known targetsequence is present in a disease-associated gene.

In some embodiments, a sample is obtained from a subject in need oftreatment for cancer. In some embodiments, the sample comprises apopulation of tumor cells, e.g., at least one tumor cell. In someembodiments, the sample comprises a tumor biopsy, including but notlimited to, untreated biopsy tissue or treated biopsy tissue (e.g.,formalin-fixed and/or paraffin-embedded biopsy tissue).

In some embodiments, the sample is freshly collected. In someembodiments, the sample is stored prior to being used in methods andcompositions described herein. In some embodiments, the sample is anuntreated sample. As used herein, “untreated sample” refers to abiological sample that has not had any prior sample pre-treatment exceptfor dilution and/or suspension in a solution. In some embodiments, asample is obtained from a subject and preserved or processed prior tobeing utilized in methods and compositions described herein. By way ofnon-limiting example, a sample can be embedded in paraffin wax,refrigerated, or frozen. A frozen sample can be thawed beforedetermining the presence of a nucleic acid according to methods andcompositions described herein. In some embodiments, the sample can be aprocessed or treated sample. Exemplary methods for treating orprocessing a sample include, but are not limited to, centrifugation,filtration, sonication, homogenization, heating, freezing and thawing,contacting with a preservative (e.g., anti-coagulant or nucleaseinhibitor) and any combination thereof. In some embodiments, a samplecan be treated with a chemical and/or biological reagent. Chemicaland/or biological reagents can be employed to protect and/or maintainthe stability of the sample or nucleic acid comprised by the sampleduring processing and/or storage. In addition, or alternatively,chemical and/or biological reagents can be employed to release nucleicacids from other components of the sample. By way of non-limitingexample, a blood sample can be treated with an anti-coagulant prior tobeing utilized in methods and compositions described herein. Suitablemethods and processes for processing, preservation, or treatment ofsamples for nucleic acid analysis may be used in the method disclosedherein. In some embodiments, a sample can be a clarified fluid sample.In some embodiments, a sample can be clarified by low-speedcentrifugation (e.g., 3,000×g or less) and collection of the supernatantcomprising the clarified fluid sample.

In some embodiments, a nucleic acid present in a sample can be isolated,enriched, or purified prior to being utilized in methods andcompositions described herein. Suitable methods of isolating, enriching,or purifying nucleic acids from a sample may be used. For example, kitsfor isolation of genomic DNA from various sample types are commerciallyavailable (e.g., Catalog Nos. 51104, 51304, 56504, and 56404; Qiagen;Germantown, MD). In some embodiments, methods described herein relate tomethods of enriching for target nucleic acids, e.g., prior to asequencing of the target nucleic acids. In some embodiments, a sequenceof one end of the target nucleic acid to be enriched is not known priorto sequencing. In some embodiments, methods described herein relate tomethods of enriching specific nucleotide sequences prior to determiningthe nucleotide sequence using a next-generation sequencing technology.In some embodiments, methods of enriching specific nucleotide sequencesdo not comprise hybridization enrichment.

Target genes and Therapeutic Applications

In some embodiments of techniques described herein, a determination ofthe sequence contiguous to a known oligonucleotide target sequence canprovide information relevant to treatment of disease. Thus, in someembodiments, methods disclosed herein can be used to aid in treatingdisease. In some embodiments, a sample can be from a subject in need oftreatment for a disease associated with a genetic alteration. In someembodiments, a known target sequence is a sequence of adisease-associated gene, e.g., an oncogene. In some embodiments, asequence contiguous to a known oligonucleotide target sequence and/orthe known oligonucleotide target sequence can comprise a mutation orgenetic abnormality which is disease-associated, e.g., a SNP, aninsertion, a deletion, and/or a gene rearrangement. In some embodiments,a sequence contiguous to a known target sequence and/or a known targetsequence present in a sample comprised sequence of a gene rearrangementproduct. In some embodiments, a gene rearrangement can be an oncogene,e.g., a fusion oncogene.

Certain treatments for cancer are particularly effective against tumorscomprising certain oncogenes, e.g., a treatment agent which targets theaction or expression of a given fusion oncogene can be effective againsttumors comprising that fusion oncogene but not against tumors lackingthe fusion oncogene. Methods described herein can facilitate adetermination of specific sequences that reveal oncogene status (e.g.,mutations, SNPs, and/or rearrangements). In some embodiments, methodsdescribed herein can further allow the determination of specificsequences when the sequence of a flanking region is known, e.g., methodsdescribed herein can determine the presence and identity of generearrangements involving known genes (e.g., oncogenes) in which theprecise location and/or rearrangement partner are not known beforemethods described herein are performed.

In some embodiments, a subject is in need of treatment for lung cancer(e.g., with EGFR-TKI, a targeted cancer therapy). In some embodiments,e.g., when the sample is obtained from a subject in need of treatmentfor lung cancer, the known target sequence can comprise a sequence froma gene selected from the group of ALK, ROS1, and RET. Accordingly, insome embodiments, gene rearrangements result in fusions involving theALK, ROS1, or RET. Non-limiting examples of gene arrangements involvingALK, ROS1, or RET are described in, e.g., Soda et at. Nature 2007448561-6: Rikova et al. Cell 2007 131:1190-1203; Kohno et al. NatureMedicine 2012 18:375-7; Takouchi et al. Nature Medicine 2012 18:378-81;which are incorporated by reference herein in their entireties. However,it should be appreciated that the precise location of a generearrangement and the identity of the second gene involved in therearrangement may not be known in advance. Accordingly, in methodsdescribed herein, the presence and identity of such rearrangements canbe detected without having to know the location of the rearrangement orthe identity of the second gene involved in the gene rearrangement.

In some embodiments, the known target sequence can comprise sequencefrom a gene selected from the group of: ALK, ROS1, and RET.

In some embodiments, the presence of a gene rearrangement of ALK in asample obtained from a tumor in a subject can indicate that the tumor issusceptible to treatment with a treatment selected from the groupconsisting of: an ALK inhibitor; EGFR; crizotinib (PF-02341066);AP26113; LDK378; 3-39; AF802; IPI-504; ASP3026; AP-26113; X-396;GSK-1838705A; CH5424802; diamino and aminopyrimidine inhibitors of ALKkinase activity such as NVP-TAE684 and PF-02341066 (see, e.g., Galkin etal., Proc Natl Acad Sci USA, 2007, 104:270-275; Zou et al., Cancer Res,2007, 67:4408-4417; Hallberg and Palmer F1000 Med Reports 2011 3:21;Sakamoto et al., Cancer Cell 2011 19:679-690; and molecules disclosed inWO 04/079326). All of the foregoing references are incorporated byreference herein in their entireties. An ALK inhibitor can include anyagent that reduces the expression and/or kinase activity of ALK or aportion thereof, including, e.g., oligonucleotides, small molecules,and/or peptides that reduce the expression and/or activity of ALK or aportion thereof. As used herein “anaplastic lymphoma kinase” or “ALK”refers to a transmembrane tyrosine kinase typically involved in neuronalregulation in the wildtype form. The nucleotide sequence of the ALK geneand mRNA are known for a number of species, including human (e.g., asannotated under NCBI Gene ID: 238).

In some embodiments, the presence of a gunk rearrangement of ROS1 in asample obtained from a tumor in a subject can indicate that the tumor issusceptible to treatment with a treatment selected from the groupconsisting of: a ROS1 inhibitor and an ALK inhibitor as described hereinabove (e.g., crizotinib). A ROS1 inhibitor can include any agent thatreduces the expression and/or kinase activity of ROS1 or a portionthereof, including, e.g., oligonucleotides, small molecules, and/orpeptides that reduce the expression and/or activity of ROS1 or a portionthereof. As used herein “c-ros oncogene 1” or “ROS1” (also referred toin the art as ros-1) refers to a transmembrane tyrosine kinase of thesevenless subfamily and which interacts with PTPN6. Nucleotide sequencesof the ROS1 gene and mRNA are known for a number of species, includinghuman (e.g., as annotated under NCBI Gene ID: 6098).

In some embodiments, the presence of a gene rearrangement of RET in asample obtained from a tumor in a subject can indicate that the tumor issusceptible to treatment with a treatment selected from the groupconsisting of: a RET inhibitor; DP-2490, DP-3636, SU5416; BAY 43-9006,BAY 73-4506 (regorafenib), ZD6474, NVP-AST487, sorafenib, RPI-1, XL184,vandetanib, sunitinib, imatinib, pazopanib, axitinib, motesanib,gefitinib, and withaferin A (see, e.g., Samadi et al., Surgery 2010148:1228-36; Cuccuru et al., JNCI 2004 13:1006-1014; Akeno-Stuart etal., Cancer Research 2007 67:6956; Grazma et al., J Clin Oncol 201028:15s 5559; Mologni et al., J Mol Endocrinol 2006 37:199-212;Calmomagno et al., Journal NCI 2006 98:326-334; Mologni, Curr Med Chem2011 18:162-175; and the compounds disclosed in WO 06/034833; US PatentPublication 2011/0201598 and U.S. Pat. No. 8,067,434). All of theforegoing references are incorporated by reference herein in theirentireties. A RET inhibitor can include any agent that reduces theexpression and/or kinase activity of RET or a portion thereof,including, e.g., oligonucleotides, small molecules, and/or peptides thatreduce the expression and/or activity of RET or a portion thereof. Asused herein, “rearranged during transfection” or “RET” refers to areceptor tyrosine kinase of the cadherin superfamily which is involvedin neural crest development and recognizes glial cell line-derivedneurotrophic factor family signaling molecules. Nucleotide sequences ofthe RET gene and mRNA are known for a number of species, including human(e.g., as annotated under NCBI Gene ID: 5979).

In some embodiments, the known target sequence can comprise a geneselected from Table 2.

TABLE 2 Known target sequences TRAN- SCRIPT NCBI Reference DI- SequencesREC- GENE (RefSeq) EXONS TION TYPE AKT3 NM_005465 1, 2, 3 5′ Fusion ALKNM_004304 19, (intron 19), 20, 21, 22 5′ Fusion ARHGAP26 NM_015071 2,10, 11, 12 5′ Fusion AXL NM_021913 19, 20 3′ Fusion BRAF NM_004333 7, 83′ Fusion BRAF NM_004333 7, 8, 9, 10, 11, 12 5′ Fusion BRAF NM_004333 155′ Fusion BRAF NM_004333 V600E n/a Mutation BRD3 NM_007371 9, 10, 11, 123′ Fusion BRD4 NM_014299 10, 11 3′ Fusion EGFR NM_005228 7, 9, 16, 20 5′Fusion EGFR NM_005228 8 (2-7 exon skipping n/a Mutation event) EGFRNM_005228 24, 25 3′ Fusion ERG NM_004449 2, 3, 4, 5, 6, 7, 8, 9, 10, 5′Fusion 11 ESR1 NM_ 3, 4, 5, 6 3′ Fusion 001122742 ETV1 NM_004956 3,4, 5,6, 7, 8, 9, 10, 11, 5′ Fusion 12, 13 ETV4 NM_001986 2, 4, 5, 6, 7, 8, 9,10 5′ Fusion ETV5 NM_004454 2, 3, 7, 8, 9 5′ Fusion ETV6 NM_001987 1, 2,3, 4, 5, 6 3′ Fusion ETV6 NM_001987 2, 3, 5, 6, 7 5′ Fusion EWSR1NM_005243 4, 5, 6,7, 8, 9, 10, 11, 12, 3′ Fusion 13, 14 FGFR1 NM_0158502, 8, 9, 10, 17 5′ Fusion FGFR2 NM_000141 2, 8, 9, 10 5′ Fusion FGFR2NM_000141 17 3′ Fusion FGFR3 NM_000142 17, Intron 17 3′ Fusion FGFR3NM_000142 8, 9, 10 5′ Fusion FGR NM_005248 2 5′ Fusion INSR NM_00020820, 21, 22 3′ Fusion INSR NM_000208 12, 13, 14, 15, 16, 17, 18, 5′Fusion 19 MAML2 NM_032427 2, 3 5′ Fusion MAST1 NM_014975 7, 8, 9, 18,19, 20, 21 5′ Fusion MAST2 NM_015112 2, 3, 5, 6 5′ Fusion MET NM_00024513 3′ Fusion MET NM_000245 13, 15 (exon 14 skipping n/a Mutation event)MSMB NM_002443 2, 3, 4 3′ Fusion MUSK NM_005592 7, 8, 9, 11, 12, 13, 145′ Fusion MYB NM_ 7, 8, 9, 11, 12, 13, 14, 15, 3′ Fusion 001130173 16NOTCH1 NM_017617 2, 4, 29, 30, 31 3′ Fusion NOTCH1 NM_017617 26, 27, 28,29 (internal 5′ Fusion exon 3-27 deletion) NOTCH2 NM_024408 5, 6, 7 3′Fusion NOTCH2 NM_024408 26, 27, 28 5′ Fusion NRG1 NM_004495 1, 2, 3, 65′ Fusion NTRK1 NM_002529 8, 10, 11, 12, 13 5′ Fusion NTRK2 NM_00618011, 12, 13, 14, 15, 16, 17 5′ Fusion NTRK3 NM_002530 13, 14, 15, 16 5′Fusion NTRK3 NM_ 15 5′ Fusion 001007156 NUMBL NM_004756 3 5′ FusionNUTM1 NM_175741 3 5′ Fusion PDGFRA NM_006206 7 (exon 8 deletion) n/aMutation PDGFRA NM_006206 10, 11, 12, 13, 14, 5′ Fusion PDGFRA NM_006206T674I, D842V n/a Mutation PDGFRB NM_002609 8, 9, 10, 11, 12, 13, 14 5′Fusion PIK3CA NM_006218 2 5′ Fusion PKN1 NM_002741 10, 11, 12, 13 5′Fusion PPARG NM_015869 1, 2, 3 5′ Fusion PRKCA NM_002737 4, 5, 6 5′Fusion PRKCB NM_002738 3 5′ Fusion RAF1 NM_002880 4, 5, 6, 7, 9 3′Fusion RAF1 NM_002880 4, 5, 6, 7, 9, 10, 11, 12 5′ Fusion RELA NM_0219753, 4 5′ Fusion RET NM_020630 8, 9, 10, 11, 12, 13 5′ Fusion ROS1NM_002944 31, 32, 33, 34, 35, 36, 37 5′ Fusion RSPO2 NM_178565 1, 2 5′Fusion RSPO3 NM_032784 2 5′ Fusion TERT NM_198253 2 5′ Fusion TFE3NM_006521 2, 3, 4, 5, 6 3′ Fusion TFE3 NM_006521 2, 3, 4, 5, 6, 7, 8 5′Fusion TFEB NM_007162 1, 2 5′ Fusion THADA NM_022065 28 3′ FusionTMPRSS2 NM_005656 1, 2, 3, 4, 5, 6 3′ Fusion TMPRSS2 NM_ 1 3′ Fusion001135099

Further non-limiting examples of applications of methods describedherein include detection of hematological malignancy markers and panelsthereof (e.g., including those to detect genomic rearrangements inlymphomas and leukemias), detection of sarcoma-related genomicrearrangements and panels thereof; and detection of IGH/TCR generearrangements and panels thereof for lymphoma testing.

In some embodiments, methods described herein relate to treating asubject having or diagnosed as having, e.g., cancer with a treatment forcancer. Subjects having cancer can be identified by a physician usingcurrent methods of diagnosing cancer. For example, symptoms and/orcomplications of lung cancer which characterize these conditions and aidin diagnosis are well known in the art and include but are not limitedto, weak breathing, swollen lymph nodes above the collarbone, abnormalsounds in the lungs, dullness when the chest is tapped, and chest pain.Tests that may aid in a diagnosis of, e.g., lung cancer include, but arenot limited to, x-rays, blood tests for high levels of certainsubstances (e.g., calcium), CT scans, and tumor biopsy. A family historyof lung cancer, or exposure to risk factors for lung cancer (e.g.,smoking or exposure to smoke and/or air pollution) can also aid indetermining if a subject is likely to have lung cancer or in making adiagnosis of lung cancer.

Cancer can include, but is not limited to, carcinoma, includingadenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, leukemia,squamous cell cancer, small-cell lung cancer, non-small cell lungcancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma,pancreatic cancer, glioblastoma, basal cell carcinoma, biliary tractcancer, bladder cancer, brain cancer including glioblastomas andmedulloblastomas; breast cancer, cervical cancer, choriocarcinoma; coloncancer, colorectal cancer, endometrial carcinoma, endometrial cancer;esophageal cancer, gastric cancer; various types of head and neckcancers, intraepithelial neoplasms including Bowen's disease and Paget'sdisease; hematological neoplasms including acute lymphocytic andmyelogenous leukemia; Kaposi's sarcoma, hairy cell leukemia; chronicmyelogenous leukemia, AIDS-associated leukemias and adult T-cellleukemia lymphoma; kidney cancer such as renal cell carcinoma, T-cellacute lymphoblastic leukemia/lymphoma, lymphomas including Hodgkin'sdisease and lymphocytic lymphomas; liver cancer such as hepaticcarcinoma and hepatoma, Merkel cell carcinoma, melanoma, multiplemyeloma; neuroblastomas; oral cancer including squamous cell carcinoma;ovarian cancer including those arising from epithelial cells, sarcomasincluding leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma,and osteosarcoma; pancreatic cancer, skin cancer including melanoma,stromal cells, germ cells and mesenchymal cells; prostate cancer, rectalcancer, vulval cancer, renal cancer including adenocarcinoma; testicularcancer including germinal tumors such as seminoma, non-seminoma(teratomas, choriocarcinoma), stromal tumors, and germ cell tumors;thyroid cancer including thyroid adenocarcinoma and medullar carcinoma;esophageal cancer, salivary gland carcinoma, and Wilms' tumors. In someembodiments, the cancer can be lung cancer.

Multiplex Methods

Methods described herein can be employed in a multiplex format. Inembodiments of methods described herein, multiplex applications caninclude determining the nucleotide sequence contiguous to one or moreknown target nucleotide sequences. As used herein, “multiplexamplification” refers to a process that involves simultaneousamplification of more than one target nucleic acid in one or morereaction vessels. In some embodiments, methods involve subsequentdetermination of the sequence of the multiplex amplification productsusing one or more sets of primers. Multiplex can refer to the detectionof between about 2-1.000 different target sequences in a singlereaction. In some embodiments, however, multiplex can refer to thedetection of between about 1,000-10,000 different target sequences in asingle reaction. In some embodiments, multiplex can refer to thedetection of between about 10,000-100,000 different target sequences ina single reaction. As used herein, multiplex refers to the detection ofany range between 2-1,000, e.g., between 5-500, 25-1,000, or 10-100different target sequences in a single reaction, etc. The term“multiplex” as applied to PCR implies that there are primers specificfor at least two different target sequences in the same PCR reaction.

In some embodiments, target nucleic acids in a sample, or separateportions of a sample, can be amplified with a plurality of primers(e.g., a plurality of first and second target-specific primers). In someembodiments, the plurality of primers (e.g., a plurality of first andsecond target-specific primers) can be present in a single reactionmixture, e.g., multiple amplification products can be produced in thesame reaction mixture. In some embodiments, the plurality of primers(e.g., a plurality of sets of first and second target-specific primers)can specifically anneal to known target sequences comprised by separategenes. In some embodiments, at least two sets of primers (e.g., at leasttwo sets of first and second target-specific primers) can specificallyanneal to different portions of a known target sequence. In someembodiments, at least two sets of primers (e.g., at least two sets offirst and second target-specific primers) can specifically anneal todifferent portions of a known target sequence comprised by a singlegene. In some embodiments, at least two sets of primers (e.g., at leasttwo sets of first and second target-specific primers) can specificallyanneal to different exons of a gene comprising a known target sequence.In some embodiments, the plurality of primers (e.g., firsttarget-specific primers) can comprise identical 5′ tag sequenceportions.

In embodiments of methods described herein, multiplex applications caninclude determining the nucleotide sequence contiguous to one or moreknown target nucleotide sequences in multiple samples in one sequencingreaction or sequencing run. In some embodiments, multiple samples can beof different origins, e.g., from different tissues and/or differentsubjects. In such embodiments, primers (e.g., tailed random primers) canfurther comprise a barcode portion. In some embodiments, a primer (e.g.,a tailed random primer) with a unique barcode portion can be added toeach sample and ligated to the nucleic acids therein; the samples cansubsequently be pooled. In such embodiments, each resulting sequencingread of an amplification product will comprise a barcode that identifiesthe sample containing the template nucleic acid from which theamplification product is derived.

EXAMPLES

The following examples are intended to illustrate certain embodimentsdescribed herein, including certain aspects of the present invention,but do not exemplify the full scope of the invention.

Example 1: Design of Technology Specific Adapter Nucleic Acids

Adapter nucleic acids and corresponding adapter primers suitable for usein various next-generation sequencing technologies were designed andgenerated.

An example of an adapter nucleic acid and adapter primers that can beused in

Illumina specific adapter nucleic acid andadapter primers Top (amplification) strand (5′→3′): (SEQ ID NO.: 1)AATGATACGGCGACCACCGAGATCTACACATCCGTACACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNAACCGCCAGGAG*T, where″N″ represents a nucleotide of a molecular barcode sequence, and ″*T″ represents a T having a phosphothioate bond.Bottom (blocking) strand (5′→3′): (SEQ ID NO.: 2)5phosCTCCTGGCGGTTt, where ″t″ represents a modified thymine nucleobase (e.g., an inverted thymine)First adapter primer (5′→3′): (SEQ ID NO.: 3) AATGATACGGCGACCACCGAGATCTASecond adapter primer (5′→3′): (SEQ ID NO.: 4)ATGATACGGCGACCACCGAGATCTACAC

As shown, the first and second adapter primers contain sequences thatare identical to a portion of the top (amplification) strand. As aresult of this design, each primer is able to prime off of complementarystrands generated by a first and second target-specific primer during afirst and second PCR step, respectively. The second adapter primer inthis example contains two additional nucleotides and is nested relativeto the first adapter primer.

An example of an adapter nucleic acid and adapter primers that can beused in Ion semiconductor specific applications is shown below:

Ion specific adapter nucleic acid and adapter primersTop (amplification) strand (5′→3′): (SEQ ID NO.: 5)CCATCTCATCCCTGCGTGTCTCCGACTCAGCTAAGGTAACNNNNNNNNGCTCTTCCGATC*T, where ″N″ represents a nucleotide ofa molecular barcode sequence, and ″*T″ representsa T having a phosphothioate bond. Bottom (blocking) strand (5′→3′):(SEQ ID NO.: 6) 5phosGATCGGAAGAGCt, where ″t″ represents amodified thymine nucleobase (e.g., an inverted thymine)First adapter primer (5′→3′): (SEQ ID NO.: 7) CCATCTCATCCCTGCGTGTCSecond adapter primer (5′→3′): (SEQ ID NO.: 8)CCATCTCATCCCTGCGTGTCTCCGACTCAG

As shown, the first and second adapter primers contain sequences thatare identical to a portion of the top (amplification) strand. As aresult of this design, each primer is able to prime off of complementarystrands generated by a first and second target-specific primer during afirst and second PCR step, respectively. The second adapter primer inthis example contains ten additional nucleotides and is nested relativeto the first adapter primer.

Example 2: Preparing a Nucleic Acid Sample for Analysis

An example of a workflow that illustrates a method of preparing anucleic acid sample for analysis is shown in FIG. 5 . A sample of RNAmolecules is annealed with random primers. This annealing can beachieved, for example, by the addition of random hexamers to the sample,followed by heating at 65° C. for 5 minutes. Following annealing, firststrand cDNA synthesis is achieved by primer extension (e.g., at roomtemperature) using a reverse transcriptase enzyme to generate a DNA/RNAhybrid.

At this point, a “PreSeq” RNA QC assay may be performed to assesslibrary complexity. Using this assay, 600 ng of random hexamers(annealed at 65° C. for 5 minutes) was compared to the use of 100 ng ofrandom hexamers (annealed at 65° C. for 5 minutes). The determination ofa “Ct” value provides an indication of library complexity and aprediction of the likelihood of molecular barcode inflation during latersteps. Generally, a threshold Ct of 28 is used as a benchmark, withvalues below this threshold being most desirable. It was found thatincreasing random primer concentration advantageously minimizes Ct.

Following the optional PreSeq assay, RNA of the DNA/RNA hybrid iscleaved, for example, by treating the sample with RnaseH. The resultingfragments of RNA that remain hybridized to the DNA serve as primers forsecond strand cDNA synthesis. This is achieved using DNA Poll andincubating the sample, e.g., at 16° C. for 60 minutes. Following thisperiod, DNA Poll is inactivated by heat (e.g., by incubating the sampleat 75° C. for 20 minutes). It was found that heat inactivation of DNAPoll greatly increased the sample integrity in subsequent samplepreparation steps.

As shown in FIG. 6 , heat inactivation of DNA Poll produced samplesshowing much cleaner bands by gel chromatography following second strandsynthesis when compared to no heat inactivation. It is postulated thatDNA Poll becomes active during end repair and is damaging fragments dueto its 5′-3′ and/or 3′-5′ exonuclease activity-heat inactivation of DNAPoll following second strand synthesis prevents this from occurring.

The double-stranded cDNA sample is subjected to end repair to blunt endthe cDNA and phosphorylate 5′ ends. In this step, an excess of T4 DNAPolymerase and T4 Polynucleotide Kinase is added to the sample alongwith sufficient dNTPs and allowed to incubate (e.g., for 30 minutes at25° C.). An AMPure cleanup (2.5×) following this period is critical, asit removes residual dATP from the library preparation before tailingwith biotin-labeled dATP. This cleanup step prevents the labeling oflibrary fragments with dATP instead of biotin-dATP, which would resultin loss of the mislabeled fragments during the capture step.

The library fragments are A-tailed at 3′ends with biotin-labeled dATP ina first ligation step using Klenow Fragment (3′-5′ exo-). This can beachieved, for example, by incubating the sample and the necessarycomponents at 37° C. for 15 minutes. An AMPure cleanup (2.5×) followingA-tailing is critical, as it removes residual biotin-labeled dATP fromthe library preparation before the capturing step. This cleanup preventsfree biotin-dATP from saturating streptavidin binding sites, resultingin loss of library fragments during capture.

In a second ligation step, adapter nucleic acids are ligated to thebiotin-A-tailed library fragments using DNA ligase. Interestingly, itwas found that the addition of a crowding agent to the ligation mixturegreatly improved ligation efficiency across all terminal bases. As shownin FIG. 7 , regardless of 5′ terminal base, the inclusion of 10% PEGfurther minimized non-ligated fragments (none) and singly-ligatedfragments (L1) while concomitantly increasing doubly-ligated fragments(L2). Moreover, adapter ligation with 10% PEG was achieved in 5 minutescompared to the “Standard” protocol that was performed in 60 minutes.Further data has shown that 20% PEG improves ligation efficiency evenfurther (not shown).

FIG. 8A depicts a nucleic acid adapter used in these experiments. Asshown, the top strand (amplification strand) contains, in 5′-3′, auniversal adapter primer site region, a sample index region, asequencing primer site region, a molecular barcode region, a 3′ duplexportion, and a 3′ T overhang. The bottom strand (blocking strand)contains a common region that is duplexed with the 3′ duplex portion ofthe top strand, a 5′ phosphorylated end, and an inverted dT base thatprevents extension of the strand.

Following adapter ligation, ligation cleanup is conducted by capture oflibrary fragments via streptavidin-coated beads. This is performed usingM-280 streptavidin dynabeads (10 mg/mL concentration stored in PBS+0.1%BSA+0.02% Azide). The storage buffer is exchanged with ligation cleanupbuffer (1 M NaCl, 1 mM EDTA, 0.1% Tween, 10 mM Tris pH 8) prior toadding the beads to the sample. The ligated DNA product (50 μL) is mixedwith ligation cleanup beads (50 μL for a total of 100 μL). A magneticfield is subsequently applied to the sample to capture libraryfragments, and the supernatant is removed. Library-bound beads are thentransferred to a separate mixture of components for a first PCR step.

A first round of PCR is performed using a first target-specific primerand a first adapter primer. The first adapter primer is identical to atleast a portion of the amplification strand, such that it anneals to thecomplementary strand generated by the first target-specific primer. Asecond round of PCR is conducted using a second target-specific primerand a second adapter primer, the latter of which is similarly identicalto a portion of the amplification strand. The second target-specificprimer is nested relative to the first target-specific primer and isfurther contacted by an additional primer.

As shown in FIG. 8B, the second target-specific primer contains a 5′tail that does not hybridize to the target-specific region. Anadditional primer is included that contains a region that is identicalto the 5′ tail along with a second sample index region and a sequencingadapter region. In this way, the second target-specific primer primesoff of the template strand to generate a complement strand having anuncommon tailed region. As in the first round of PCR, the second adapterprimes off of this complementary strand to generate a copy of thetemplate strand. As this copy of the template strand will contain aregion that is complementary to the 5′ tail sequence, the additionalprimer containing the second sample index region and sequencing adapterregion will prime off of this sequence to generate a bottom strand thatis ready for sequencing.

Equivalents

While several inventive embodiments have been described and illustratedherein, those of ordinary skill in the art will readily envision avariety of other means and/or structures for performing the functionand/or obtaining the results and/or one or more of the advantagesdescribed herein, and each of such variations and/or modifications isdeemed to be within the scope of the inventive embodiments describedherein. More generally, those skilled in the art will readily appreciatethat all parameters, dimensions, materials, and configurations describedherein are meant to be exemplary and that the actual parameters,dimensions, materials, and/or configurations will depend upon thespecific application or applications for which the inventive teachingsis/are used. Those skilled in the art will recognize, or be able toascertain using no more than routine experimentation, many equivalentsto the specific inventive embodiments described herein. It is,therefore, to be understood that the foregoing embodiments are presentedby way of example only and that, within the scope of the appended claimsand equivalents thereto, inventive embodiments may be practicedotherwise than as specifically described and claimed. Inventiveembodiments of the present disclosure are directed to each individualfeature, system, article, material, kit, and/or method described herein.In addition, any combination of two or more such features, systems,articles, materials, kits, and/or methods, if such features, systems,articles, materials, kits, and/or methods are not mutually inconsistent,is included within the inventive scope of the present disclosure.

All definitions, as defined and used herein, should be understood tocontrol over dictionary definitions, definitions in documentsincorporated by reference, and/or ordinary meanings of the definedterms.

All references, patents and patent applications disclosed herein areincorporated by reference with respect to the subject matter for whicheach is cited, which in some cases may encompass the entirety of thedocument.

The indefinite articles “a” and “an,” as used herein in thespecification and in the claims, unless clearly indicated to thecontrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in theclaims, should be understood to mean “either or both” of the elements soconjoined, i.e., elements that are conjunctively present in some casesand disjunctively present in other cases. Multiple elements listed with“and/or” should be construed in the same fashion, i.e., “one or more” ofthe elements so conjoined. Other elements may optionally be presentother than the elements specifically identified by the “and/or” clause,whether related or unrelated to those elements specifically identified.Thus, as a non-limiting example, a reference to “A and/or B”, when usedin conjunction with open-ended language such as “comprising” can refer,in one embodiment, to A only (optionally including elements other thanB); in another embodiment, to B only (optionally including elementsother than A); in yet another embodiment, to both A and B (optionallyincluding other elements); etc.

As used herein in the specification and in the claims, “or” should beunderstood to have the same meaning as “and/or” as defined above. Forexample, when separating items in a list, “or” or “and/or” shall beinterpreted as being inclusive, i.e., the inclusion of at least one, butalso including more than one, of a number or list of elements, and,optionally, additional unlisted items. Only terms clearly indicated tothe contrary, such as “only one of” or “exactly one of,” or, when usedin the claims, “consisting of,” will refer to the inclusion of exactlyone element of a number or list of elements. In general, the term “or”as used herein shall only be interpreted as indicating exclusivealternatives (i.e. “one or the other but not both”) when preceded byterms of exclusivity, such as “either,” “one of,” “only one of,” or“exactly one of.” “Consisting essentially of,” when used in the claims,shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “atleast one,” in reference to a list of one or more elements, should beunderstood to mean at least one element selected from any one or more ofthe elements in the list of elements, but not necessarily including atleast one of each and every element specifically listed within the listof elements and not excluding any combinations of elements in the listof elements. This definition also allows that elements may optionally bepresent other than the elements specifically identified within the listof elements to which the phrase “at least one” refers, whether relatedor unrelated to those elements specifically identified. Thus, as anon-limiting example, “at least one of A and B” (or, equivalently, “atleast one of A or B,” or, equivalently “at least one of A and/or B”) canrefer, in one embodiment, to at least one, optionally including morethan one, A, with no B present (and optionally including elements otherthan B); in another embodiment, to at least one, optionally includingmore than one, B, with no A present (and optionally including elementsother than A); in yet another embodiment, to at least one, optionallyincluding more than one, A. and at least one, optionally including morethan one, B (and optionally including other elements); etc.

It should also be understood that, unless clearly indicated to thecontrary, in any methods claimed herein that include more than one stepor act, the order of the steps or acts of the method is not necessarilylimited to the order in which the steps or acts of the method arerecited.

In the claims, as well as in the specification above, all transitionalphrases such as “comprising,” “including,” “carrying,” “having,”“containing,” “involving,” “holding,” “composed of,” and the like are tobe understood to be open-ended, i.e., to mean including but not limitedto. Only the transitional phrases “consisting of” and “consistingessentially of” shall be closed or semi-closed transitional phrases,respectively, as set forth in the United States Patent Office Manual ofPatent Examining Procedures, Section 2111.03. It should be appreciatedthat embodiments described in this document using an open-endedtransitional phrase (e.g., “comprising”) are also contemplated, inalternative embodiments, as “consisting of” and “consisting essentiallyof” the feature described by the open-ended transitional phrase. Forexample, if the disclosure describes “a composition comprising A and B”,the disclosure also contemplates the alternative embodiments “acomposition consisting of A and B” and “a composition consistingessentially of A and B”.

What is claimed is:
 1. A method of preparing nucleic acids for analysis,the method comprising: (a) adding one or more nucleotides to a 3′ end ofa double-stranded nucleic acid comprising a target nucleotide sequence,wherein at least one of the one or more nucleotides is a capture moietymodified nucleotide; (b) ligating an adapter nucleic acid to at leastone strand of the double-stranded nucleic acid to produce a ligationproduct comprising the one or more capture moiety modified nucleotides;and (c) capturing the ligation product by contacting the ligationproduct with a binding partner of the capture moiety modifiednucleotide.
 2. The method of claim 1, further comprising, after thecapturing of (c): (d) amplifying the ligation product.
 3. The method ofclaim 2, wherein the amplifying comprises linear amplification or apolymerase chain reaction.
 4. The method of claim 3, wherein thepolymerase chain reaction comprises use of a first target-specificprimer that specifically anneals to a portion of the target nucleotidesequence and a first adapter primer that specifically anneals to acomplementary sequence of the adapter nucleic acid.
 5. The method ofclaim 4, further comprising amplifying a product of (d) by a secondpolymerase chain reaction that comprises (i) use of a second adapterprimer that specifically anneals to a complementary sequence of theadapter nucleic acid, and (ii) use of a second target-specific primerthat specifically anneals to a portion of the target nucleotide sequenceand is nested relative to the first target-specific primer.
 6. Themethod of claim 1, further comprising, after the capturing of (c),determining a sequence of at least a portion of the double-strandednucleic acid.
 7. The method of claim 1, wherein the double-strandednucleic acid comprises genomic DNA, fragmented DNA, cell-free DNA(cfDNA) or cDNA.
 8. The method of claim 1, wherein after the adding of(a), the double-stranded nucleic acid comprises a 3′-overhang sequence.9. The method of claim 8, wherein the 3′-overhang sequence iscomplementary to one or more nucleotides at a 3′ end of the adapternucleic acid.
 10. The method of claim 1, wherein each of the one or morenucleotides is a capture moiety modified nucleotide.
 11. The method ofclaim 1, wherein only one nucleotide is added to the 3′ end of thedouble-stranded nucleic acid in step (a), wherein the one nucleotide isa capture moiety modified nucleotide.
 12. The method of claim 11,wherein the one nucleotide comprises adenine.
 13. The method of claim 1,wherein the capture moiety modified nucleotide comprises a biotincapture moiety.
 14. The method of claim 1, wherein the capturing of (c)provides an immobilized ligation product, and the method furthercomprises washing the immobilized ligation product, releasing theimmobilized ligation product, and amplifying at least a portion of theligation product.
 15. The method of claim 1, wherein the adapter nucleicacid comprises a barcode and a primer binding site.
 16. The method ofclaim 1, wherein the adapter nucleic acid is double-stranded.
 17. Amethod of preparing nucleic acids for analysis, the method comprising:(a) adding one or more nucleotides to a 3′ end of each of a plurality ofdouble-stranded nucleic acids comprising a plurality of different targetnucleotide sequences, wherein at least one of the one or morenucleotides is a capture moiety modified nucleotide; (b) ligating anadapter nucleic acid to at least one strand of each of the plurality ofdouble-stranded nucleic acids to produce a plurality of ligationproducts comprising the one or more capture moiety modified nucleotides;(c) capturing the plurality of ligation products by contacting theplurality of ligation products with a binding partner of the capturemoiety modified nucleotide; and (d) amplifying the plurality of ligationproducts, thereby providing a plurality of amplicons.
 18. The method ofclaim 17, wherein the plurality of double-stranded nucleic acidscomprises 25 to 1000 different target nucleotide sequences or 1000 to10,000 different target nucleotide sequences.
 19. A method of preparingnucleic acids for analysis, the method comprising: (a) adding one ormore nucleotides to a 3′ end of a double-stranded nucleic acidcomprising a target nucleotide sequence, wherein at least one of the oneor more nucleotides is a capture moiety modified nucleotide; (b)ligating an adapter nucleic acid to at least one strand of thedouble-stranded nucleic acid to produce a ligation product comprisingthe one or more capture moiety modified nucleotides; (c) capturing theligation product by contacting the ligation product with a bindingpartner of the capture moiety modified nucleotide, thereby providing animmobilized ligation product; (d) optionally washing the immobilizedligation product; (e) separating the ligation product from the bindingpartner; and (f) amplifying the separated ligation product of (e) by apolymerase chain reaction using a first target-specific primer thatspecifically anneals to the target nucleotide sequence and a firstadapter primer that specifically anneals to a complementary sequence ofthe adapter nucleic acid.
 20. The method of claim 19, wherein thecapture moiety modified nucleotide comprises a biotin capture moiety.21. The method of claim 19, wherein the binding partner comprises anavidin protein.
 22. A method of preparing nucleic acids for analysis,the method comprising: (a) combining a double-stranded nucleic acid, amodified nucleotide comprising a capture moiety, and an enzyme underconditions in which the enzyme adds the modified nucleotide to a 3′ endof the double-stranded nucleic acid; (b) combining the double-strandednucleic acid, an adapter nucleic acid, and a ligase under conditions inwhich the ligase ligates the adapter nucleic acid to the double-strandednucleic acid, thereby producing a ligation product comprising thecapture moiety; and (c) combining the ligation product and a bindingpartner of the capture moiety under conditions in which the bindingpartner forms a complex with the ligation product.